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1. INTRODUCTION 
1.1 Early-onset epileptic encephalopathies 
Early-onset epileptic encephalopathies (EIEE) are a heterogeneous group of rare and 
severe neurological disorders, characterized by intractable epilepsy within the first 
period of life, which results in devastating global developmental delay and intellectual 
disability. Patients have impaired cognitive, sensory and motor development, leading 
to lack of motor, language and social development (Duszyc, Terczynska et al. 2015). 
EIEEs are genetically and phenotipically heterogeneous and, recently, 25 genes have 
been identified as causative for these pathologies (Tab.1). Further, different kind of 
mutations within each gene gives rise to a broad spectrum of phenotypes.  
 
 
Table 1 Summary of 25 genes involved in early infantile epileptic encephalopathies (Duszyc, 
Terczynska et al. 2015). 
 
For these reasons, unfortunately, there are not specific treatments for the patients. 
However, some patients respond to common anti-epileptic drugs (AED). For other 
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patients, hormonal treatments have been used, such as corticosteroids. Some are 
resistant to pharmacotherapy and have been used surgery and neurostimulation. 
Since an early diagnosis of EIEE is difficult given the variety and heterogeneity of 
clinical features, there are several studies directed to unravel the etiopathogenesis 
and genetical basis of these pathologies in order to detect responsible genes and 
assign specific therapies.   
   
1.2 PCDH19-female limited epilepsy, EIEE9 
The following section will provide a brief explanation of the main features of the 
pathology caused by PCDH19 mutations, to give some elucidation and discuss about 
the possible mechanism of action and involvement of this protein in the pathology. 
PCDH19-female limited epilepsy (PCDH19-FLE) is classified as early infantile 
epileptic encephalopathy type 9 (EIEE9) and is characterized by seizure onset in 
infancy or early childhood (6-36 months) and cognitive impairment (Dibbens, Tarpey 
et al. 2008).  
1.2.1 Clinical features 
Affected infants appear normal until 4-18 months, then they begin to have partial and 
generalized febrile convulsions that gradually increase in frequency and are 
accompained by developmental regression. Patients experience a variety of 
generalized and focal seizure types: these mostly consist in generalized tonic, clonic 
or tonic-clonic, and/or focal seizures with or without secondary generalization. In 
most cases seizures are resistant to treatment, especially to the AEDs. In most 
females, the frequency of seizures decline dramatically by the age of 2-3 years and 
stop in some cases in adolescence, but intellectual disability generally persists after 
seizure remission (Depienne and LeGuern 2012).  
Moreover, behavioral disturbances are frequent and essentially manifest as autistic, 
obsessive, or aggressive features. Intellectual outcome ranges from normal intellect 
to mild, moderate, or severe cognitive impairment (Depienne and LeGuern 2012).  
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In conclusion, this pathology is characterized by heterogeneous phenotypic spectrum 
that range from severe generalized or multifocal epilepsy, resembling Dravet 
syndrome, to more benign focal epilepsies with normal intelligence.  
1.2.2 Causative gene and mutations 
The disorder was first described in 1971 by Juberg and Hellman in 15 related females 
with early onset grand mal seizures and mental retardation. It was mapped more 
than 20 years later on chromosome X: in particular, linkage analysis narrowed the 
FLE locus to an approximately 34-megabase region of the X chromosome (Ryan, 
Chance et al. 1997). 
Only in 2008 the gene encoding protocadherin-19 (PCDH19) was identified as the 
gene mutated in FLE. Recently, several studies showed that PCDH19-FLE is more 
frequent than expected; in particular it represents the 16% of cases in the SCN1A-
negative Dravet syndrome-like patients. PCDH19 is now considered the second gene, 
after SCN1A, most clinically relevant in epilepsy.     
The same authors that found PCDH19 as causative gene of FLE, identified different 
PCDH19 gene mutations in all the seven families with PCDH19-FLE analyzed: five 
mutations resulted in the introduction of a premature termination codon (Dibbens, 
Tarpey et al. 2008). 
Over time, during the last years, several studies identified more than 100 pathogenic 
point mutations (missense, nonsense, splicing, small deletion/insertion, whole gene 
deletion) in the PCDH19 gene (Figure 1).  
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Figure 1 Schematic representation of PCDH19 sequence and the most common point mutations that 
cause PCDH19-FLE. Above the mRNA there are nonsense mutations, while below are reported the 
missense mutations. The number from 1 to 6 represent the exons of PCDH19 protein (Duszyc, 
Terczynska et al. 2015).     
 
In particular, the most frequently FLE causative mutations are point mutations, even 
if there are rare cases in which also gross whole-gene or intragenic deletions have 
been reported. In any case, these mutations lead to degradation of mRNA and loss of 
PCDH19 protein expression. Indeed, half of the missense pathologic allelic variants 
result in the appearance of premature termination codons that result in a truncated 
form of the mRNA, degradated by non-mediated decay (NMD) process. Interestingly, 
there are also evidences of PCDH19 gene duplication in at least two cases: a male with 
only cognitive impairment and a female with focal epilepsy (van Harssel, Weckhuysen 
et al. 2013). 
As indicated in Figure1, the majority of the mutations identified are located in the 
large PCDH19 extracellular domain containing the cadherin repeats and residues that 
are thought to be involved in calcium binding, damaging therefore adhesiveness of 
the protein (Dibbens, Tarpey et al. 2008, Jamal, Basran et al. 2010). Mutations in the 
cytoplasmic tail seem to be more tolerated as indicated by the numerous non 
pathological polymorphisms identified (Hynes, Stone et al. 2011). 
1.2.3 PCDH19-FLE mode of inheritance and pathogenic mechanism 
A peculiar feature of PCDH19-FLE is its unusual inheritance pattern. Indeed, even if 
the causative gene is located on the X-chromosome, mutations are not transmitted in 
the common way, neither as X-linked dominant nor X-linked recessive mode (Figure 
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2). In particular, it spares hemizygous males carring PCDH19 mutations and affects 
heterozygous females (Dibbens, Tarpey et al. 2008, Marini, Mei et al. 2010, Specchio, 
Marini et al. 2011). 
 
 
 
 
Figure 2 Schematic representation of unusual X-linked female restricted inheritance, resembling that 
of PCDH19-FLE (a) in comparison to X-linked dominant (b) and X-linked recessive (c) patterns. (a) 
Only heterozygous females are affected, while hemizygous males transmit mutations, but remain 
unaffected. (b) Males and females carrying mutations are affected. Affected males never transmit the 
disease to their sons. (c) Hemizygous males carrying a mutation and homozygous females for a 
mutation exhibit the symptoms of the disease. Usually, transmitting heterozygous females are 
unaffected (Duszyc, Terczynska et al. 2015). 
 
Further, despite the unique inheritance pattern of PCDH19-FLE, there are rare cases 
of females carring PCDH19 mutations that are asymptomatic. Furthermore, even for 
the same mutations, the clinical manifestations vary from mild to severe (Dibbens, 
Tarpey et al. 2008, Dimova, Kirov et al. 2012). Till now there are no cases of females 
carring the homozygous PCDH19 mutation, while in very rare cases mosaic males 
affected have been identified (Depienne, Bouteiller et al. 2009). 
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Given the peculiarity regarding the inheritance pattern of the pathology, three models 
have been hypothesized three models that try to give an explanation to PCDH19-FLE 
transmission mode. 
The first and second models try to explain the presence of healthy hemizygous males. 
The first hypothesis suggests that there is an homologous gene in males on the Y 
chromosome expressed in each cell that can compensate for the loss of function of the 
mutated PCDH19.  
The second model assumes that PCDH19 gene produces a protein that is not essential 
for brain development since this protein belongs to a family composed by more than 
70 elements that have overlapping expression in brain and, for this, maybe their 
expression can compensate the loss of function of mutated form of PCDH19 (Ryan, 
Chance et al. 1997, Dibbens, Tarpey et al. 2008). 
The last hypothesis gives an explanation for females and mosaic males affected by 
PCDH19-FLE. It contemplates the random X-inactivation, since the PCDH19 gene is 
located in a region submitted to X inactivation in females. In particular, this model 
considers the idea that heterozygous females manifest a tissue mosaicism with 
random ratio between cells that have inactivated the mutated PCDH19 allele and 
express the normal protein, and PCDH19-negative cells that have inactivated the 
normal allele. This mosaicism could account for the pathogenesis by scrambling the 
cell-cell communication. The loss of function of PCDH19 at the level of the cell would 
thus result in a gain of function at the tissue level because of abnormal interactions 
between “mutated” and “normal” cells. A mechanism of this type is termed “cellular 
interference” (Figure 3) (Ryan, Chance et al. 1997, Dibbens, Tarpey et al. 2008, 
Depienne, Bouteiller et al. 2009, Depienne and LeGuern 2012). This model is 
supported by the identification of an affected male that is a mosaic for mutated and 
wild type PCDH19 (Depienne, Bouteiller et al. 2009). 
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Figure 3 Schematic illustration of “cellular interference” mechanism proposed for PCDH19 mutations. 
(A) Absence of PCDH19 mutations, in which all cells are phenotipically homogeneous, express PCDH19 
wt protein and are able to form normal neuronal networks; (B) Mutated males in which all the cells are 
PCDH19-negative, so, also in this case, are phenotipically homogeneous and able to form normal 
neuronal connections that do not affect normal development of these individuals; (C) Heterozygous 
mutated females in which random X-inactivation leads to the co-existence of two PCDH19-positive and 
PCDH19-negative cell populations. These two different kind of cells are no more able to form normal 
neuronal network since there are attractive or repulsive interactions that lead to divergent cell sorting 
and migration. Somatic mosaicism in mutated males is proposed to generate the same pathological 
situation (Depienne, Bouteiller et al. 2009). 
 
Anyway, all of phenotypes heterogeneity supports the fact that there are different 
factors that act concomitantly to produce the heterogeneous and various phenotypes 
in patients carring PCDH19 gene mutations. The genotype and the presence of 
different genes, that can act as modifier of phenotype, may play an important role in 
the clinical outcome of mutations. Further, the extent of mosaicism, so the percentage 
of mutated cells, could has a relevant influence on the manifestation of different 
phenotypes, leading to several degrees of heterogeneity in cell population that reflect 
various clinical outcome (Depienne, Trouillard et al. 2010).  
However, a clear explanation of the pathological mechanism that leads to a variety of 
clinical outcomes is still lacking. So, it is important to analyze PCDH19 function in 
brain to better define this pathology.  
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1.3 PCDH19 and protocadherin family proteins 
The following section will describe protocadherins family and mainly PCDH19 
protein, in order to highlight what is known about this protein and what is still 
missing.    
1.3.1 The protocadherin family proteins 
Cadherins are cell adhesion molecules encoded by genes classified into several 
subfamilies: the classical cadherin (Type I and II), the protocadherins and 
desmosomal cadherins. This enormous superfamily contains a large number of 
transmembrane proteins with extracellular domains that mediate calcium-dependent 
intercellular interactions. 
The protocadherin (Pcdh) family represents the widest subgroup within the cadherin 
superfamily. It is composed by almost 80 members of type I integral membrane 
proteins. Interestingly, a common feature of these family members is the presence of 
a single large exon that codes for the entire extracellular and transmembrane 
domains and also for a small portion of the C-terminal tail (Nollet, Kools et al. 2000, 
Wu, Zhang et al. 2001). Another characteristic that distinguishes these proteins from 
other cadherins is the frequent occurrence of alternative splice variants.  
Based on structural differences between the different protocadherin genes, these 
family members are classified into several subgroups: α-, β- and ƴ-protocadherins, 
which are clustered in a small genomic region; CELRS protocadherins, that contain 
seven-pass transmembrane domains; Fat-like protocadherins, that contain more than 
seven extracellular domains; the novel subgroup of non clustered δ-protocadherins 
and other protocadherins with different origins but still sharing similar structure 
domains with other cadherin members.  
The δ-protocadherin subgroup has been recently identified and it comprises nine 
protocadherins. δ-protocadherins are divided into two subgroups: δ1- and δ2- 
protocadherins. δ1 group comprises protocadherin-1, -7, -9 and -11, which are the 
only protocadherins with seven extracellular cadherin domains and, beside the 
common motif 1 and 2 (CM1 and CM2) contain one more common motif 3 (CM3). The 
δ2-protocadherins comprise protocadherin-8, -10, -17, -18 and -19, are composed by 
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six extracellular cadherin domains and do not have the CM3 motif in their 
cytoplasmic domain (Wolverton and Lalande 2001, Redies, Vanhalst et al. 2005, 
Vanhalst, Kools et al. 2005). 
1.3.2 Protocadherins functions  
There are very few studies about the functional role of protocadherins. Since they 
belong to the cadherin superfamily, the first function that was analyzed is their 
capability to mediate cell adhesion. The results demonstrated that they are able to 
interact in trans to form intercellular connections but the binding seems to be weaker 
compared to that of classical cadherins. Interestingly, it was also demonstrated that 
protocadherins are able to mediate adhesion at synaptic junctions. Indeed they are 
predominantly expressed in the brain, and are though to play significant roles in 
neurodevelopment during neuronal migration and in synaptic plasticity. Even if there 
are few works about their neuronal role, protocadherins appear to be important for 
circuit and synapses formation and, interestingly, there are new investigations that 
are focusing more in protocadherins intracellular signalling than in cell-cell adhesion 
(Depienne, Gourfinkel-An et al. 2012). 
Indeed, there are evidences that pcdhs play an important role at intracellular level 
both by their binding partners and by nuclear regulations following proteolytic 
processing. 
Concerning the first point, several works demonstrated that C-terminal domains of 
some protocadherins can interact with various common partners, such as protein 
phosphatase-1α (PP1α) for δ1-protocadherin members, the tyrosine kinase Fyn for α-
protocadherin proteins, and the microtubule-destabilizing protein SCG10 for ƴ-
protocadherin members (Kohmura, Senzaki et al. 1998, Gayet, Labella et al. 2004). 
Regarding the proteolytic processing, recently it has been shown that protocadherins 
such as ƴ-protocadherin and Fat-1 can be cleaved releasing their C-terminal domains 
that to go into the nucleus (Hambsch, Grinevich et al. 2005, Magg, Schreiner et al. 
2005, Smalley, Brafford et al. 2005). 
Altogether these findings highlight the important role of protocadherins in linking 
extracellular with intracellular signalling trough interacting proteins or gene-
expression regulation in the nucleus. 
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1.3.3 Protocadherin-19 gene and protein 
PCDH19 gene is located in Xq22.1 and is orientated in a telomere to centromere 
direction (Depienne, Gourfinkel-An et al. 2012). 
PCDH19 is conserved in dog, cow, mouse, rat, chicken and zebrafish (Entrez Gene) 
species, and has been found to be moderately expressed in all regions of the human 
brain (Dibbens, Tarpey et al. 2008). 
The complete 3,447-bp ORF of PCDH19 consists of six exons, with a large first exon 
encompassing over half of the mRNA length. The transcript is subject to alternative 
splicing that gives rise to three different isoforms: the first isoform (isoform 1) is 
without the exon 2; the second isoform (isoform 2) lacks the second exons and the 
amino acid 893; the third isoform (isoform 3) maintains the second exon and the 
amino acid 893. 
The gene encodes a 1,148 amino acids (aa) transmembrane protein belonging to the 
δ2-subclass of non-clustered pcdhs (Dibbens, Tarpey et al. 2008). 
PCDH19 contains a signal peptide of 23 aa, six calcium-dependent extracellular 
cadherin (EC) repeats that mediate cell-cell interactions and are homologous to those 
of classical cadherins, a short transmembrane domain and a cytoplasmic region with 
two conserved and characteristic δ-protocadherins CM1 and CM2 domains (Figure 4), 
(Dibbens, Tarpey et al. 2008).  
The first exon encodes for the entire extracellular and transmembrane domain and 
for a small initial part of the C-terminal tail. The rest of the cytoplasmic domain is 
encoded by exons 2-6 and, in particular, exons 5 and 6 encode CM1 and CM2 
respectively (Figure 4). 
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Figure 4 Scheme of PCDH19 gene and protein structure. Human X-chromosome and genomic of the 
PCDH19 gene. Closest flanking genes with their orientations are indicated by arrows. The lower part of 
the figure represents PCDH19 protein structure. Exons (E1-6), signal peptide (SP), extracellular 
domains (EC1-6) and the two common regions (CM1 and CM2) are shown (Dibbens, Tarpey et al. 
2008).  
 
1.3.4 PCDH19 gene expression 
As mentioned above, PCDH19 gene is widely expressed in the human brain, but it was 
also detected in primary skin fibroblasts, kidney and other tissues (Gaitan and 
Bouchard 2006). 
However, in situ hybridization analysis in the developing mouse and human central 
nervous system revealed that pcdh19 is expressed predominantly in neural tissues at 
different developmental stages.   
In mice PCDH19 mRNA has widespread expression in both the embryonic and adult 
brain, including the developing cortex and hippocampus. Interestingly, in embryos, as 
many other protocadherins, pcdh19 shows an elaborate expression profile in neural 
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tissues, meaning that its region-specific expression depends on the embryonic stage 
(Figure 5), (Gaitan and Bouchard 2006). 
 
 
Figure 5 Early expression of PCDH19 gene investigated in mice embryos by in situ hybridization. A and 
B represent the whole mount, C is a sagittal cryosection. (A) At E9.5, Pcdh19 transcript is detected in 
the brain and presomitic mesoderm. (B) At E10.5, brain expression is maintained and additional 
expression is detected in the brachial arches, otic vesicles, limb buds and caudal nephric duct. (C) In 
E12.5 embryos, high mRNA levels were observed in specific regions of the brain, in the epithelium 
lining the nasal cavity, spinal cord, stomach region and dorsal mesenteries. Ba=branchial arch; 
di=diencephalons; dmes=dorsal mesentery; ep=epiphysis; fb=forebrain; hb=hindbrain; lb=limb bud; 
mb=midbrain; nd=nephric duct; oe=olfactory epithelium; ov=otic vesicle; psm=presomitic mesoderm; 
sc=spinal cord; st=stomach (Gaitan and Bouchard 2006). 
 
Regarding the human PCDH19 gene expression, RT-PCR approaches showed its 
expression in various adult human tissues, such as brain, kidney, lung and trachea. In 
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neural tissues, PCDH19 gene was shown to be expressed in developing cortical plate, 
amygdala and subcortical regions and in the ganglionic eminence (Dibbens, Tarpey et 
al. 2008, Depienne and LeGuern 2012).  
Further, a recent study on PCDH19 expression in adult rat brain, in particular in 
hippocampal formation, revealed that this gene is expressed with a specific pattern 
showing temporal preferences, suggesting that PCDH19 may have a role in the 
formation and maintenance of hippocampal circuits. This consideration is supported 
by the investigation of PCDH19 hippocampal expression changes after 
electroconvulsive shock (ECS). Results show that PCDH19 mRNA levels are influenced 
by direct electrical brain stimulation suggesting a PCDH19 role in structural 
rearrangements of the hippocampus (Kim, Mo et al. 2010). 
Altogether these findings about PCDH19 gene expression are in accordance with the 
clinical features of FLE, especially cognitive impairment, epilepsy, autism and 
behavioral disturbances. 
1.3.5 PCDH19 protein functional role   
The biological role of the PCDH19 protein is not known. There are very few studies 
which revealed that other δ2-pcdhs mediate calcium-dependent cell-cell adhesion in 
vitro and cell sorting in vivo and could regulate the establishment of neuronal 
connections during brain development and/or remodeling of selective synaptic 
connections during the early postnatal stage (Dibbens, Tarpey et al. 2008). 
However, in contrast to cadherins, which associate through strong homophilic 
interactions, the extracellular domain of PCDH19 exhibits specific but weak 
homophilic adhesive properties (Depienne, Gourfinkel-An et al. 2012). 
Recently, two studies performed on zebrafish, demonstrated that PCDH19 and N-
cadherin are able to interact through their extracellular domains to form a complex 
and acting together to regulate cell movements during anterior neurulation in 
embryos. These evidences demonstrate that physically and functional interactions 
between PCDH19 and N-cadherin are essential for brain morphogenesis suggesting 
that protocadherins may act as cofactors for cadherin function at least during 
vertebrate development (Biswas, Emond et al. 2010, Emond, Biswas et al. 2011).   
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1.4 Proteolytic cleavage  
The following section will provide a brief explanation of proteolytic cleavage, since 
our results demonstrate that PCDH19 protein is cleaved in response to neuronal 
activity.  
In these last years, an increasing number of studies describe a new picture in which 
cells can rely signals from the extracellular space to their interior through presenilin-
dependent proteolysis within the membrane-spanning regions of type I integral 
membrane proteins to generate potential transcriptionally active intracellular 
fragments.  
Presenilin carries the active site of ƴ-secretase enzyme, which is responsible for this 
kind of cleavage. In particular, ƴ-secretase complex is a multisubunit aspartyl 
protease composed by four proteins: presenilin (PS), nicastrin, anterior pharynx-
defective 1 (Aph1) and presenilin enhancer 2 (Pen2) (McCarthy, Twomey et al. 2009). 
Initially, the ƴ-secretase complex was discovered as an essential element for the 
cleavage of β-amiloid precursor protein to generate Aβ peptides and, for this reason 
there are a lot of works that are interested in PS1/ƴ-secretase complex activity in 
Alzheimer disease (De Strooper, Saftig et al. 1998).  
Recently, new findings reveal that the same proteolytic process occurs in an 
increasing growing number of integral membrane proteins, providing unexpected 
insights into general basic mechanisms of cell signaling functions (Schroeter, 
Kisslinger et al. 1998, Gu, Misonou et al. 2001, Okamoto, Kawano et al. 2001, 
Marambaud, Shioi et al. 2002). 
In particular, this new general method for cellular communication between 
extracellular and intracellular environment is called regulated intramembrane 
proteolysis (RIP) and is characterized by two sequential cleavages. The first process 
is mediated by extracellular metalloproteases that usually shed the extracellular 
domain of the protein releasing it in the extracellular environment, thus leaving the 
intracellular domain tethered to the membrane. This fragment is sequentially cleaved 
by ƴ-secretase complex that releases a soluble intracellular domain (usually called as 
17 
 
ICD) that either acts as second messengers in the cytoplasm or enters the nucleus and 
regulates gene expression (Figure 6).  
 
 
Figure 6 Schematic representation of proteolytic process RIP. Extracellular domain is first cleaved by 
metalloproteases and is exctracellularly released. Subsequently intracellular domain (ICD) is released 
in the cytoplasm by a second cleavage mediated by ƴ-secretase enzyme (Golde, Ran et al. 2012). 
 
Within the new substrate that undergo to this proteolytic cleavage there are proteins 
implicated in synapse remodeling and maintenance, including EphRs, ephrins and 
cadherins (Dalva, McClelland et al. 2007, McCarthy, Twomey et al. 2009). 
Interestingly, PS1 has been shown to bind classical cadherins such as E-cadherin and 
N-cadherin (Georgakopoulos, Marambaud et al. 1999, Baki, Marambaud et al. 2001). 
Remarkably, E-cadherin also seems to be proteolytical processed by two sequential 
cleavage steps, even if its second cleavage site, differently from those of the other 
known ƴ-secretase substrates, does not seems to reside within the transmembrane 
but rather right at the membrane-cytosol interface (Marambaud, Shioi et al. 2002). 
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Further, in this case, ƴ-secretase enzyme could act also on the full-length E-cadherin, 
suggesting that a first cleavage by metalloproteases is not always necessary for ƴ-
secretase action (Marambaud, Shioi et al. 2002). 
Indeed, a recent study evidenced that the site of proteolysis varies among the 
different substrates, even if it remains close to the membrane-cytosol interface within 
the transmembrane sequence. Moreover there is not a unique consensus sequence for 
ƴ-secretase enzyme, although a Valine residue right after the cleavage site is present 
in most cases. 
The precise location of ƴ-secretase proteolytic machinery is still unclear. In 
particular, the ƴ-secretase localizes in neurons mainly in membranes of endosomes, 
even if recent works demonstrate that it could be present also at the plasma 
membrane, in particular in synaptic complexes together with its substrates 
(Georgakopoulos, Marambaud et al. 2000, Kaether, Haass et al. 2006). These finding 
suggest a new role for this proteolytic machinery, in particular it could modulate 
synaptic function.  
As a confirm of the newly discovered role for ƴ-secretase proteolytic machinery at 
synapses, recent works demonstrate that cadherin substrate for this enzyme undergo 
to proteolytic cleavage after neuronal activity, in particular mediated by NMDA 
receptors activation, such as for N-cadherin and ƴ-protocadherin (Reiss, Maretzky et 
al. 2006, Uemura, Kihara et al. 2006, Restituito, Khatri et al. 2011). 
 
1.5 Synapse-to-nucleus signaling  
We demonstrated that C-terminal domain of PCDH19 is able to shuttle between 
cytoplasm to nucleus in hippocampal neuronal cells. For this reason, this section will 
provide a brief overview on synapse to nucleus communications, highlighting recent 
discovery on protein messengers.   
For neuronal cells it is fundamental to converge and integrate in the nucleus synaptic 
signals to determine a genomic response that regulates gene expression in response 
to neuronal activity. This process is critical for proper neuronal functions, such as 
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neuronal development, plasticity and survival. For these reasons, synapse-to-nucleus 
communication plays an important role.  
The classical view of this process involves calcium ions as principal messenger, but 
recently there are substantial evidences, that for this type of signaling it is necessary 
also the nuclear import of cytosolic proteins. 
Supporting this concept, recent studies showed that proteins enriched at neuronal 
synapses can accumulate in the nucleus in response to synaptic activity (Jordan, 
Fernholz et al. 2007, Proepper, Johannsen et al. 2007, Dieterich, Karpova et al. 2008, 
Lai, Zhao et al. 2008). Indeed, proteomic experiments identified many proteins in 
purified synaptosomes that contain a nuclear localization sequence (NLS), indicating 
a dual nuclear and synaptic localization of these synaptic junction proteins(Husi, 
Ward et al. 2000, Jordan, Fernholz et al. 2004). 
Further, components of the classical nuclear import machinery (α-importin and β-
importin) are also present at synapse and translocate to the nucleus in response to 
neuronal activity, specifically after N-methyl-D-aspartate receptor (NMDA) 
stimulation (Thompson, Otis et al. 2004). 
All of these indications suggest that classical nuclear import mechanisms facilitate 
synapse-to-nucleus transport (Jordan, Fernholz et al. 2004). 
However, it is unclear how synaptic nuclear messengers dissociate from synapses and 
by which mechanisms they are translocating to the nucleus. 
1.5.1 Types of retrograde synapse-to-nucleus communications 
Neurons utilize multiple mechanisms for signaling between distal subcellular 
compartments and the nucleus. These methods can be divided into two major classes: 
the first one is a rapid communication involving calcium ions, while the second is 
slower than calcium propagation and requires physical translocation of signaling 
molecules. 
 Rapid communications 
Rapid communications are mediated by calcium ions flux and could be due to 
electrochemical signaling or to regenerative calcium waves in the ER.  
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In particular, the first mechanism allows extremely rapid communication to the cell 
body and nucleus. Action potentials lead to rapid influx of calcium ions at the soma 
activating calcium-sensitive signaling cascades that in turn activate transcription 
factors, thereby coupling neuronal activity to changes in gene expression within 
minutes (Figure 7) (Adams and Dudek 2005, Bengtson, Freitag et al. 2010, 
Hardingham and Bading 2010). 
The second calcium-dependent nuclear signaling method in neurons involves 
regenerative calcium waves propagated along endoplasmic reticulum (ER). Besides 
its functions in the secretory pathway, the ER is an internal calcium store that is 
continuous with the nuclear membrane and extends into distal axons and dendrites. 
In this way, through the activation of two calcium receptors present on ER surface 
(the inositol triphosphate receptor and ryanodine receptor) the calcium influx is 
regenerated and propagates toward the nucleus through voltage gated channels 
activated at cell surface (Figure 7).  
 Physical translocation of signaling molecules     
The physical transport of signaling molecules from their starting site to the nucleus is 
slower than calcium propagation and can persists over greater lengths of time. It 
comprises different mechanisms: in particular, this type of signaling includes passive 
diffusion or active transport of soluble signaling molecules and transport of signaling 
endosomes.   
A difficult point of synapse-to-nucleus trafficking is the distance of messenger 
proteins that have to communicate from distal synapse to the nucleus. It is unlikely 
that diffusion-mediated signaling is efficient enough to allow distally generated 
signals to reach the nucleus in adequate concentration to alter transcription. Indeed, 
differently from the active transport, long distance travels without directionality 
don’t permit the signal molecules to reach the nucleus with information enough to 
modulate transcriptional events, since the signal is degradate during the travel. This 
kind of diffuse transport is efficient only for small molecules and short distances 
(Howe 2005, Kholodenko, Hancock et al. 2010). Thereby, diffusion along a define axis 
could provide a fast and efficient mechanism for transport across large distances.  
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It could be along axis either without energy consume or active transport energy-
dependent. In the first case messenger proteins moves along microtubule by 
Brownian motion or by facilitated diffusion interacting with guide molecules. In 
energy-dependent transport, molecules are shuttled along dendrites to nucleus by 
association with motor proteins, such as dynein, that allow long distance trafficking 
along microtubules. An important advantage of active transport in compare with 
passive diffusion is that motor proteins have directionality and processivity. 
An example of this kind of transport is the internalization of signaling molecules into 
signaling endosomes. Once they arrives in the soma, the active complex interacts with 
a range of kinases or second messenger molecules. These secondary elements 
activate transcription factors to trigger gene expression in the nucleus (Figure 7) 
(Delcroix, Valletta et al. 2003, Ye, Kuruvilla et al. 2003, Cosker, Courchesne et al. 
2008). Further, supporting the evidence that classic import nuclear machinery could 
be involved in long distance transport of synaptic messengers in the nucleus, it was 
observed that importins associate with the dynein motor complex, suggesting that 
this transport might require microtubules.    
 
Figure 7 Representation of major synapse-to-nucleus communication pathways in neuronal cells after 
neuronal activity. Influx of calcium ions from the soma to the nucleus by activated receptors or by 
regenerative ER calcium waves. Diffusion of soluble molecules by simply Brownian motion or by 
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facilitated diffusion. Active retrograde transport mediated by molecular motors protein, such as dynein 
(Jordan and Kreutz 2009). 
1.5.2 The role of NMDA receptor in synapse-to-nucleus communications 
Recent studies identified synaptic proteins that shuttle from cytoplasm or synaptic 
sites into the nucleus in response to NMDA receptors (NMDARs) activation (Jordan, 
Fernholz et al. 2007, Proepper, Johannsen et al. 2007, Dieterich, Karpova et al. 2008, 
Lai, Zhao et al. 2008). 
NMDARs play a central role in activity-dependent gene expression, in particular their 
activation is crucial for the control of plasticity-related gene expression and long-
term memory formation. 
NMDAR itself might function as nuclear signaling platform. Indeed this receptor 
complex is a particularly rich source of proteins that are capable to translocate into 
the nucleus (Husi, Ward et al. 2000, Pocklington, Cumiskey et al. 2006). Further, one 
of NMDAR subunit, the GluN1, in particular the -1a splice isoform, contains a classical 
NLS to which α-importin is docked and regulate its association and disponibility to 
signaling molecules through phosphorylation of serine adjacent the NLS (Jeffrey, 
Ch'ng et al. 2009). In fact, changes in the phosphorylation state induced by NMDARs 
activity play a role in the association of proteins messenger with importins, regulating 
their localization in neuronal cells, leading them to be transported into the nucleus 
after NMDARs activation.  
Finally, recent studies showed that NMDAR-induced proteolytical cleavage of the 
protein messenger is a prerequisite for their nuclear transport. Indeed, in support to 
the hypothesis that proteolysis has a role in activity-dependent nuclear signaling, it 
has been demonstrated that soluble intracellular domains generated after proteolytic 
process of cellular adhesion molecules (CAMs) can accumulate in the nucleus and 
regulate gene expression (this was observed for N-cadherin, Notch, APP, ƴ-
protocadherin etc..) (Marambaud, Wen et al. 2003, Uemura, Kihara et al. 2006).   
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1.6 Epigenetic modifications and histone lysine demethylation 
The following section will provide a brief overview of histone lysine demethylase 
action on chromatin to explain the role of this enzyme in regulation of gene 
expression, since we observed that PCDH19 is able to interact with one of this histone 
lysine demethylase. 
   
Several epigenetic modifications of DNA and histones, such as acetylation, 
methylation, phosphorylation and ubiquitination modulate chromatin structure and 
dynamics, playing important role in multiple biological processes, including 
neurogenesis.  
Histones methylation is a fundamental posttranslational event that modulates 
chromatin state of condensation, regulating also transcriptional activity of different 
genes. Indeed, histones H3 and H4 can have different methylated lysines and, 
depending on the location and degree (mono-, di- or tri-methylation) of these 
modifications, the consequences could be either the repression or the activation of 
gene transcription (Martin and Zhang 2005, Mosammaparast and Shi 2010). In 
particular, H3 lysine 4 (H3-K4) di-methylation/tri-methylation (H3K4-me2/3) is 
usually associated with activation of gene transcription, whereas H3-K9 di-
methylation/tri-methylation (H3K9-me2/3) is associated with a high level of 
chromatin condensation, corresponding to gene transcription repress state. 
Interestingly, it has always been thought that histones lysine methylation was an 
irreversible chromatin modification, but recent studies demonstrate the existence of 
enzymes able to reverse this state. In particular, these enzymes can be divided at least 
into two classes of histone lysine demethylases: the Jumonji C-terminal domain 
(JmjC)-containing enzymes and the amine oxidase-related enzymes. Subsequently, 
other members of histone demethylase were discovered through sequence homology 
(Martin and Zhang 2005, Mosammaparast and Shi 2010). 
These discoveries evidence the reversible state of histone lysine methylation like all 
other histone modifications, highlighting the crucial involvement of histone lysine 
demethylases for many chromatin-based cellular processes.    
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1.6.1 Lysine-specific demethylase 1 (LSD1) 
The first histone demethylase that was identified is lysine-specific demethylase-1 
(LSD1, also known as KDM1) that belongs to the superfamily of the flavin adenine 
dinucleotide (FAD)-dependent amine oxidases (Shi, Matson et al. 2005). Initially it 
was identified as a member of an HDAC-containing, transcriptional repressor 
complex (Ballas, Battaglioli et al. 2001, Shi, Matson et al. 2005). In particular, the first 
evidence showed that it is capable to remove mono- and di-methylation of histone H3 
at lysine 4 (H3K4-me1/2) repressing, as a consequence, gene transcription. 
Subsequently, it was demonstrated that it is able to aggregate with other complexes, 
beyond Co-REST, and to be recruited to other gene promoters to demethylate H3K4-
me1/2 and to repress transcription (Saleque, Kim et al. 2007, Wang, Scully et al. 2007, 
Wang, Hevi et al. 2009). LSD1 capability to be regulated by target gene recruitment 
and substrate specificity link its functions to a variety of biological events, such as 
development, differentiation, cancer and neurological disorders (Forneris, Binda et al. 
2008, Nottke, Colaiacovo et al. 2009). 
In particular, there are evidences that suggest an important role for LSD1 in neural 
differentiation. Further, inhibition of LSD1 activity leads to a dramatically reduced 
proliferation of mouse neural stem cells (Sun, Alzayady et al. 2010, Sun, Ye et al. 
2011), while LSD1/CoREST complex control radial migration of cortical neurons 
being essential for their correct development (Fuentes, Canovas et al. 2012). 
LSD1 structure and function is conserved from yeast to human (Dallman, Allopenna 
et al. 2004, Lakowski, Roelens et al. 2006). The lsd1 gene contains 19 exons and the 
human protein consists of 852 amino acids and comprises three major parts: the N-
terminal SWIRM domain, involved in protein interactions, the C-terminal amine 
oxidase domain (AOD), consisting of two lobes which contains an insertion that forms 
the CoREST interacting site, and a long stalk formed by the insert between the two 
halves of AOD (Chen, Yang et al. 2006, Stavropoulos, Blobel et al. 2006).  
An important characteristic of lsd1 gene is that through RNA alternative splicing, two 
additional exons can be included in the mature mRNA (exon E2a and exon E8a), 
generating, in this way, four possible LSD1 isoforms: the conventional LSD1, LSD1 
with exon E2a (LSD1 +2a), LSD1 with exon E8a (LSD1 +8a) and LSD1 with both exons 
(LSD1 +2a+8a). Interestingly, LSD1+2a is present in all tissues, while the inclusion of 
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the 12-nt-long exon E8a limited the expression of the two isoforms (LSD+8a and 
LSD+2a+8a) in neuronal tissues. 
1.6.2 NeuroLSD1 isoform 
In mouse neurons, neuroLSD1 isoforms (LSD1+8a and LSD1+2a+8a) represent an 
important proportion of the total LSD1 transcripts pool (30%-40%) and during the 
perinatal period LSD1+8a is the predominantly expressed isoform (Zibetti, Adamo et 
al. 2010, Rusconi, Paganini et al. 2015). Indeed, during mouse brain development the 
expression of LSD1+8a isoforms is regulated (Zibetti, Adamo et al. 2010). 
The characteristic of LSD1+8a isoform is the gene transcription activation, differently 
from the repressor action of LSD1. In fact, LSD1+8a demethylases the lysine 9 on 
histone H3, acting on the di-methylated form of this lysine (H3K9-me2) and, further, 
compromise LSD1 abilities to demethylate H3K4. LSD1+8a isoform is able to solve 
this action only through the collaboration with different factors, such as supervillin 
protein (SVIL), depending also by developmental mouse brain stage (Laurent, Ruitu 
et al. 2015) (Figure 8). 
 
 
 
Figure 8 Schematic representation of LSD1 and neuroLSD1 action on gene expression regulation. LSD1 
demethylases histone lysine 4 leading to a repression of non-neuronal gene transcription. LSD1+8a 
isoform demethylases histone lysine 9 usually by aggregation with cofactors such as SVIL, activating 
neuronal gene transcription (Laurent, Ruitu et al. 2015). 
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Besides the several roles of LSD1 in neuronal migration and development, its 
neuronal isoforms, which activate gene transcription, solve other important neuronal 
functions. In particular, the preponderant expression of neuroLSD1 during perinatal 
period suggests that it plays an important role for neuronal development. Indeed, 
some works demonstrate that LSD1+8a is involved in neurite morphogenesis and 
neuronal development by upregulating, during neuronal maturation, those set of 
genes involved in mitosis or microtubule cytoskeleton organization pathways, which 
are important for neurogenesis (Zibetti, Adamo et al. 2010, Laurent, Ruitu et al. 
2015). 
Further, neuroLSD1 plays important role in adult mouse brain contributing to 
maintain a correct balance between neuronal excitation/inhibition (Rusconi, Paganini 
et al. 2015). Indeed, neuroLSD1-null mice display a modified threshold of excitability, 
with a reduced susceptibility to Pilocarpine-induced status epilepticus (PISE), while 
mouse model of Rett Syndrome is characterized by an elevate seizures susceptibility 
have neuroLSD1 overexpression (Guy, Hendrich et al. 2001, Nan and Bird 2001, 
Rusconi, Paganini et al. 2015). 
For these reasons, it is fundamental to maintain a correct ratio between LSD1 and 
neuroLSD1 during the entire life period of brain, in order to have specific chromatin 
modifications that regulate transcription of genes involved in neuronal development 
and excitatory/inhibitory balance.    
1.6.3 NOVA1 and the importance of LSD1 alternative splicing 
RNA binding proteins (RNABPs) regulate neuronal development and activity, playing 
a critical role in the brain.  
NOVA proteins are RNBPs that are present in mammals in two paralogs: NOVA1 and 
NOVA2, which are largely expressed in the central nervous system (Buckanovich, 
Posner et al. 1993, Yang, Yin et al. 1998). These proteins regulate splicing, are able to 
shuttle between nucleus and cytoplasm and co-localize with target transcripts in 
dendrites. It was demonstrated that NOVA translocates into cytoplasm after neuronal 
activity and that mediates large changes in synaptic proteins, including proteins 
implicated in familial epilepsy. Further, mice that have haploinsufficient NOVA 
protein, manifest spontaneous epilepsy. These evidences linked NOVA to neuronal 
27 
 
activity, in particular it became important in mediated homeostatic 
excitation/inhibition in neuronal cells. 
One of the NOVA target is LSD1, in particular this RNABP positively modulate exon 
E8a splicing inclusion generating neuroLSD1 isoform. In this way, neuronal activity 
modulates changes in LSD1/neuroLSD1 ratio by NOVA action, highlighting the crucial 
role of neuroLSD1 in modulation of neuronal excitability (Figure 9) (Rusconi, 
Paganini et al. 2015). 
 
 
Figure 9 Model that link development, genetic background and electrical activity to excitability. 
Different LSD1/neuroLSD1 ratio is regulated by alternative splicing mediated by NOVA1 and nSR100 
protein. Various balance between LSD1 and its neuronal isoform are associated with different degrees 
of neuronal excitability (Rusconi, Paganini et al. 2015). 
 
These findings open to new clinical perspectives, in particular give rise to possibility 
to treat hyperexcitability-associated neurological disorders modulating neurospecific 
splicing of LSD1.  
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2. AIM OF THE PROJECT 
 
PCDH19-female limited epilepsy, also known as early infantile epileptic 
encephalopathy type 9, is characterized by seizures onset in infancy or early 
childhood, cognitive impairment and behavioral disturbances. PCDH19 gene, located 
at the X-chromosome, is the causative gene and till now have been identified more 
than 100 different pathogenic point mutations which lead to degradation of mRNA 
and loss of PCDH19 protein expression (Duszyc, Terczynska et al. 2015). 
A peculiar feature of PCDH19-FLE is the unusual inheritance pattern. Indeed, 
differently from the common X-linked pathology, FLE spares hemizygous males 
carring PCDH19 mutations and affects heterozygous females (Dibbens, Tarpey et al. 
2008, Marini, Mei et al. 2010, Specchio, Marini et al. 2011). Further, there are various 
phenotypic degrees, even between patients carrying the same mutation. There are 
several hypothesis that try to explain the pathogenic mechanism. However a clear 
and precise explanation is still lacking.  
Further, little is known about the expression and functions of PCDH19 protein 
encoded by the FLE causative gene.  
Thus, the principal aim of our work is to go deeper into PCDH19 physiological 
functions in order to understand which kind of pathways could be impaired in 
patients and highlight crucial points altered in pathological conditions that could 
represent new therapeutic targets.  
The first part of our work aimed to define PCDH19 expression in rat brain and in 
neuronal cells. In particular we investigated PCDH19 expression level in different 
adult rat brain regions and we analyzed the subcellular localization of PCDH19 in 
cultured hippocampal neurons.   
In the second part of the work we investigated PCDH19 neuronal functions, in 
particular we examined a new molecular mechanism by which PCDH19 could link 
external stimuli with intracellular compartment focusing more on its putative 
intracellular functions than the extracellular.  
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The third part of the work aimed to go deeper into nuclear function of PCDH19-CTF. 
Firstly we investigated the effect of PCDH19 loss in cultured hippocampal neurons. 
We used a shRNA strategy that induces loss of expression of PCDH19 resembling 
PCDH19-FLE condition and analyzes which targets are impaired by PCDH19 
knockdown. 
Then, once we obtained putative targets, we went deeper into the molecular and 
functional mechanism that links PCDH19 protein to these targets in order to clarify 
the pathways in which PCDH19 plays an important role and that could be impaired by 
the loss of PCDH19 expression.   
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3. MATERIALS AND METHODS   
3.1 cDNA constructs, shRNAs 
The full-length PCDH19 isoform4 coding sequence was subcloned from pcDNA/V5 
construct (gift from Joseph Gecz) cFUW (Addgene) vector using AscI/BamHI 
restriction enzymes in order to obtain PCDH19-V5 and for production of lentivirus.   
CT-HA construct was obtained by PCR from PCDH19 sequence in pcDNA/V5 
construct using these primers: 5’ cgggatccatggcaatcaagtgcaagcgagac 3’ and 5’ 
gaagatctcatgagaacgatatccttcagacg 3’. The PCR product was inserted pCMV vector with 
the hemagglutinin (HA)- tag at C-terminal. 
In order to produce PCDH19 shRNAs, the sequences 5’ agaaccactcgtacctttaat 3’ 
(shRNA 1873), 5’ acaaagagatccggacctaca 3’ (shRNA 2120), 5’ gagcagcatgaccagtacaat 
3’ (shRNA 1240) were used and inserted into the pLL3.7 vector (Rubinson, Dillon et 
al. 2003); the same sequences were inserted into pLVTHM for production of 
lentivirus. The shRNAs were specific only for rat sequences. The scramble constructs 
were generated using these sequences: 5' gacagtattcatcccacatta 3' for sh1873, 5' 
gagcacactgcgaatcacaaa 3' for sh2120, 5' gaacagcatcccgaagtgtaa 3' for sh1240. 
GST-PCDH19 construct, made with C-terminus (wt, aa 700-1148) was cloned into the 
E.Coli plasma vector pGEX-4T-1. 
NOVA1, LSD1 and neuroLSD1 cDNAs with hemagglutinin (HA)-tag at C-terminal were 
a gift from Battaglioli’s laboratory. 
CT-V5 construct was obtained by PCR from PCDH19 sequence in pcDNA/V5 construct 
using these primers: 5’ cgggatccatggcaatcaagtgcaagcgagac 3’ and 5’ 
aggcgcgccctaaccggtacgcgtagaatc 3’. The PCR product was inserted into cFUW/RFP 
vector using BamHI/AscI restriction enzymes. CT-V5 and cFUW/RFP vector were 
used for production in lentivirus. 
The truncated form of PCDH19 isoform4 (aa 1-844) was amplified by PCR from 
PCDH19-pcDNA/V5 using this primer for C-terminal 5’ 
aggcgcgccgtcaaaagaatagttttcagt 3’. The truncated form was cloned in lentiviral vector 
cFUW/RFP using BamHI/AscI restriction enzymes. 
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PCDH9 coding sequence was inserted into pIRES2 vector (gift from Fengmin Lu). 
 
3.2 Cell cultures, transfection and infection 
Human Embryonic Kidney 293 cells (HEK293) and African green monkey kidney cells 
(COS-7) at 50-70% confluence (24h after plating onto 6-well plates or onto glass 
coverslips in 12-well plates) were transiently transfected with cDNA expression 
constructs (1.8-3 ug/well) using Jet-PEI solution (Polyplus-transfection). The 
transfected cells were grown for 24-48 hours before fixation for 
immunocytochemistry or lysis for coimmunoprecipitation and GST pulldown.  COS-7 
and HEK293 cells were mainteined in Dulbecco’s modified Eagle medium plus 10% 
fetal bovine serum and 1% penicillin/Streptomycin. The HEK293 cell line for 
generating lentivirus was grown in 1% G418, an aminoglycoside antibiotic.  
Primary hippocampal neurons were prepared from embryonic days 18-19 rat brains 
(Brewer, Torricelli et al. 1993) and plated on coverslips coated with poly-D-lysine 
(0,25mg/ml) at 75.000/well for immunochemistry and 300.000/well for 
biochemistry experiments. Cultured neurons were transfected using the calcium 
phosphate method as described in (Lois, Hong et al. 2002). Immature neurons were 
transfected or infected at DIV4-11 and fixed or lysated at DIV7-19. 
Lentiviruses expressing shRNAs, scrambled, full-length or C-terminal PCDH19 protein 
were produced using HEK293 cells as described by (Lois, Hong et al. 2002). 
 
3.3 Culture treatments 
COS-7, HEK293 cells and hippocampal mature neurons (DIV15-19) were treated after 
removing one-half of the culture conditioned medium (CM) and  replaced with fresh 
medium. Reagents were added to the cultures: MG132, DAPT and DRB 10 μM for 1.30 
hour; NMDA (50 μM), AP5 (100 μM) for 30 min; BIC (10 μM) and TTX (20 μM) for 1 
hour (all of these compounds were from Sigma Aldrich). After treatments cells were 
fixed or lysed, for ICC, fractionation or immunoblotting experiments. 
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3.4 GST-pull down assay and Co-Immunoprecipitation  
GST fusion proteins were prepared in E.coli strain BL21 and purified according to 
standard procedures. HEK293 cells and were lysed with a standard lysis buffer (PBS, 
1% Triton X-100, 1mM EDTA, protease inhibitor cocktail, pH 7.4). 
The lysates were incubated with 30μg GST fusion protein immobilized on 
glutathione-Sepharose 4B beads (GE Healthcare) for 3 hours at 4°C, wash 3-5 times in 
lysis buffer and resuspended in 25μl 3X SDS sample buffer. GST alone was used as 
control.  
Samples were separated by SDS-PAGE followed by Western blotting with appropriate 
antibodies.  
For immunoprecipitation experiments, HEK293 cells (homogenization buffer: 50mM 
TRIS-HCl, 200mM NaCl, 1 mM EDTA, 1%NP40, 1% Triton X-100, pH 7.4, protease 
inhibitor cocktail) were centrifuged at 16.500 g for 20 min at 4°C and supernatants 
were incubated at 4°C with Protein A-agarose beads (GE Healthcare) conjugated with 
rabbit IgG (6ug/ml SIGMA). The beads were separated by centrifugation and the 
supernatants were incubated at 4°C for 4 hours with protein A beads conjugated with 
either anti-V5 rabbit or anti-HA rabbit (6 μg/ml) or, as control, IgG (6 μg/ml). Then 
the beads were washed three times with lysis buffer and twice with PBS plus protease 
inhibitors and after resuspension in 3X sample buffer by boiling them for 5 minutes, 
were analyzed by SDS-PAGE.  
The following antibodies and dilutions were used for immunoprecipitation: HA 
(1:1000 Invitrogen), V5 (1:400 Invitrogen), PCDH9 (1:400 AbCam)(all raised in 
rabbit) and PCDH19 (1:400, AbCam, raised in mouse). The secondary antibodies were 
horseradish peroxidase-conjugated anti-rabbit or anti-mouse IgG, light chain (both 
from 1:70000 Jackson ImmunoResearch laboratories) (RT, 1h in 5% milk). 
Immunoreactive bands were visualized by enhanced chemiluminescence 
(PerkinElmer). 
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3.5 Biotinylation assay  
Plasma membrane proteins were biotinylated using membrane-impermeant sulfo-
NHS-SS-biotin (0,3 mg/ml, Pierce) for 5 minutes at 37°C. Labeled neurons were 
washed with TBS supplemented with 0,1 mM CaCl2, 1mM MgCl2 and 50 mM glycine. 
After 3 washes with TBS supplemented with 0,1 mM CaCl2 and 1mM MgCl2 on ice, 
cells were lysed in extraction buffer (50 mM Tris-HCl, pH 7.4, 1 mM EDTA, 150 mM 
NaCl, 1% SDS, and protease inhibitors).  
Lysates were boiled for 5 minutes, quantify with BCA kit (ThermoScientific) and, after 
kept the inputs, immunoprecipitated with streptavidin-conjugated magnetic beads 
(Dynabeads, Invitrogen). 
The fractions obtained (input, biotinylated and intracellular components) were 
resuspended in 3X sample buffer, boiled for 5 minutes and analyzed by SDS-PAGE.  
 
3.6 Isolation of crude synaptosomes 
Adult mice brains were homogenized using cold homogenization buffer (0.32 M 
sucrose, 10 mM HEPES pH7.4, 2 mM EDTA, protease and phosphatase inhibitors) and 
spined at 1000g for 15 min to separate pelleted nuclear fraction (P1). The 
supernatant (S1) was recovered and centrifuged at 10.000g to produce a crude 
synaptosomal pellet (P2) and a supernatant (S2) which contains the cytosol and the 
light membranes. Synaptosomal pellet was resuspended in hepes buffer (50 mM 
Hepes pH 7.4, 2 mM EDTA, protease and phosphatase inhibitors). Samples were 
separated using SDS-PAGE and visualized by immunoblotting. 
 
3.7 Subcellular fractionation of primary cell cultures (Cos-7, 
HEK293) 
Primary culture cells were washed once with PBS and lysed in appropriate buffer (75 
mM NaCl, 50 mM TrisHCl pH 7.4, 1% Np40, proteases and phosphatases inhibitors). 
After 1 hour of homogenization at 4°C they were centrifuged at 13.200 rpm for 10 
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min at 4°C. The surnatant were collected and centrifuged at 12.500 g for 10 minutes 
at 4°C in order to obtained the surnatant (S2) containing membrane and cytosol and 
pellet (P2) containing nuclear compartment. All these fractions (total homogenate, S2 
and P2) were resuspended in 3X sample buffer, boiled for 5 minutes at 100°C and 
separated using SDS-PAGE.  
 
3.8 Subcellular fractionation of primary neuronal cells  
Two week-old high-density cultures of rat hippocampal neurons treated with NMDA 
and NMDA+AP5 were lysed in PBS. Subsequently were homogenate in hypotonic 
buffer (10 mM Hepes pH 7.5, 0.5% NP-40, 10 mM KCl, 1mM EDTA, 1mM DTT, 
protease and phosphatase inhibitors). After 15 min of mild agitation, cells were 
centrifuged at 400g for 10 min at 4°C. The supernatant was then centrifuged at 
15.000g for 10 min at 4°C to clarify the extract and the supernatant (S1), representing 
the cytosolic/membrane enrich fraction, was collected. The pellet (P1) obtained from 
the 400g centrifugation was treated with an hypertonic buffer (20 mM Tris-HCl 
pH7.5, 0.6 M NaCl, 0.2 mM EDTA, 1.4 mM MgCl2, 25% glycerol, protease and 
phosphatase inhibitors) and centrifuged at 80.000g for 10 min at 4°C. The 
supernatant (S2) was collected and represented the soluble nuclear-enriched 
fraction, while the pellet (P2) was resuspended in SB3X and represented the nuclear 
aggregates-enriches fraction. All the fractions were separated using SDS-PAGE and 
visualized by immunoblotting. 
 
3.9 SDS-PAGE, western-blot analysis and antibodies 
Brain homogenization was performed in RIPA buffer (TrisHCl pH 7.4 50mM, NaCl 150 
mM, EDTA 1mM, NP40 1%, Triton 1% and protease inhibitors). 
Cellular lysis was performed as previously indicated. Proteins were separated in 10% 
SDS-PAGE and electroblotted onto nitrocellulose membranes in buffer containing 
0.025 M Tris-HCl, 0.192 M glycine, 20% methanol, pH 8.3 at 80 V for 120 min. 
Immunoblotting reactions were performed by incubating with the primary antibodies 
35 
 
(RT, 2-3h in 5% milk): -rabbit abs anti: GAPDH (1:2000, Santa Cruz), HA (1:1000, 
Invitrogen), V5 (1:1000, Invitrogen), LSD1 (1:1000, MBL) or mouse anti: α-tubulin 
(1:10000, SIGMA), PCDH19 (1:400, AbCam), GFP (1:2000, Roche Applied Science), 
PSD95 (1:20000, NeuroMab), Synaptophysin (1:1000, SIGMA). 
Horseradish peroxidase-conjugated anti-rabbit or anti-mouse antibodies (1:2000 GE 
Healtcare) were used as secondary antibodies (RT, 1h in 5% milk). Immunoreactive 
bands were visualized by enhanced chemiluminescence (ECL, PerkinElmer). 
Quantification analyses were performed using ImaJ software.  
 
3.10 Total RNA extraction and RT-PCR analysis 
After specific neuronal cells infections or treatments, total RNA was isolated using the 
Trizol reagent (Sigma-Aldrich) and the purified RNA was treated with RNase-free 
DNase set (Qiagen) to remove any residual DNA.  
Quantitative RT-PCR analysis was performed on an iQ5 Real-Time PCR Detection 
System (Biorad) using the iScriptTM two-step RT-PCR Kit with SYBR® Green (Biorad).  
These experiments were performed in collaboration with Battaglioli’s laboratory.  
 
3.11 Immunofluorescence and antibodies 
Hippocampal neurons or COS7 cells were fixed in 4% paraformaldeyde/4% sucrose 
for 8-10 minutes at room temperature and incubated with rabbit anti: V5 (1:400, 
Invitrogen), HA (1:100, Invitrogen), NOVA-1(1:400, SIGMA), GluA1 (1:1000, 
Chemicon), GAD 65/67 (1:400, MilliporMerck); with mouse anti: PCDH19 (1:200, 
AbCam) or with Guinea Pig anti: MAP2 (1:20000, Synaptic System) in GDB1X solution 
(2X: gelatin 2%, Triton X100 10%, 0.2 M Na2HPO4 pH 7.4, 4 M NaCl) for 2-3 hours at 
room temperature or over night at 4°C.  
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Then, cells were washed and incubated with Alexa 488 (1:400, Invitrogen), Alexa 555 
(1:400, Invitrogen) or Cy5 (1:200, Jackson Immunoresearch) secondary antibodies 
diluted in GDB1X solution for 1 hour at room temperature. 
 
3.12 Image acquisition and quantification  
Confocal images were obtained using a Nikon 40x and 60x objectives with sequential 
acquisition setting at 1024x1024 pixels resolution. Each image was a ‘z’ series 
projection of approximately 7 to 12 images taken at 0.75 μm depth intervals, except 
that regarding nuclear compartment which are single stacks. Transfected or infected 
neurons were chosen randomly for quantification from two to five coverslips from 
three to five independent experiments. Morphometric and fluorescence intensity 
measurements were performed using MetaMorph images analysis software 
(Universal Imaging, West Chester, PA) and ImageJ. Statistical comparisons were 
performed with appropriate statistical test.  
 
3.13 Statistical analysis 
Data were expressed as mean ± standard error of the mean (SEM). Statistical 
significance was assessed using the paired and unpaired Student’s t test as 
appropriate (for two group comparisons) or ANOVA followed by Bonferroni’s post 
hoc tests. The level of significance was taken as: *p < 0.05, **p<0.01, ***p<0.001. All 
statistical analyses were performed using Prism 6 software (GraphPad, San Diego, 
CA). Each in vitro experiment was repeated at least three times. Primary neurons 
from three independent preparations were used.  
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4. RESULTS 
4.1 PCDH19 is highly expressed in cortex and hippocampus and 
localizes at synapse 
We first investigated PCDH19 localization in adult rat brain by western blotting 
experiments. Quantification analysis of PCDH19 levels showed that it is highly 
expressed in cortex and hippocampus, regions where we focused our attention, while 
it is less expressed in the cerebellum (Figure 10A).  
Moreover, adult mouse brain fractionation shows the presence of PCDH19 in crude 
synaptosomes, together with PSD95 and synaptophysin markers  (P2 fraction, Figure 
10B).  
These results suggest that PCDH19 is involved in cognitive processes, in accordance 
with the clinical aspects of the pathology, since PCDH19-FLE is characterized by 
epileptic seizures, intellectual disability and autism (Specchio, Marini et al. 2011).  
Further, PCDH19 belongs to the cadherin superfamily, that is composed by cell 
adhesion transmembrane molecules mainly involved in intercellular interactions. 
Those, we performed biotinylation experiments on mature cultured hippocampal 
neurons (DIV19) to analyze PCDH19 cellular distribution. The results showed that 
PCDH19 localizes both at neuronal surface and intracellularly (Figure 10C). In 
addition, immunocytochemistry (ICC) on both COS-7 cells and hippocampal neurons 
overexpressing PCDH19 protein revealed that it is recruited at cell-cell contacts, 
suggesting a role of PCDH19 in intercellular interactions and adhesion (Figure 10D). 
These findings indicate that PCDH19 has a potential role in cognitive processes and 
intercellular communications, since it is highly expressed in hippocampus, synaptic 
compartment and neuronal surface. 
 
4.2 PCDH19 distributes both in developing and mature 
hippocampal neurons  
We decided to further investigate temporal and spatial expression of PCDH19 protein 
in hippocampal neurons in order to go deeper into PCDH19 neuronal functions.  
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ICC on PCDH19 endogenous protein in developing hippocampal cells revealed that it 
is abundantly expressed in immature neurons (DIV4), while distributes 
heterogeneously in mature cells (DIV18, Figure 11A). Moreover, in neurons at DIV12 
PCDH19 distributes along dendritic shaft, while in mature neurons it acquires 
punctuated pattern at synaptic level (Figure 11B).  
Finally, we analyzed in which type of neuronal cells it is preferentially localized. ICC 
experiments on mature hippocampal neurons revealed that it is expressed both in 
inhibitory and in excitatory cells, colocalizing partially both with PSD95 and α1-
GABAA receptor subunit (Figure 11C). 
Its presence both in immature and mature hippocampal neurons suggests a putative 
role for PCDH19 in neuronal development. Further, since it is expressed both in 
inhibitory and excitatory cells, we could hypothesized that PCDH19 has different 
roles according to the type of neurons it is expressed.    
 
4.3 Proteolytic cleavage of PCDH19 protein in heterologous cells 
Several recent studies reveal a new intracellular role of some cadherins besides their 
adhesion functions. In particular, some of these proteins, such as N-cadherin and ƴ-
protocadherin, are cleaved by different enzymes. Usually, in the first step, the 
extracellular domain is released after metalloproteases action and, subsequently, a 
second enzyme cleaves intracellularly releasing the cytoplasmic domain of the 
protein in the cytosol. As a consequence, these protein’s domains are able to solve 
intracellular signaling functions (Junghans, Haas et al. 2005). 
Looking at PCDH19 protein sequence, we identified a motif in the transmembrane 
domain that is common among ƴ-secretase substrates. Moreover, by informatic tools, 
we found out a putative nuclear localization sequence (NLS) at the C-terminal domain 
that could transport the C-terminal tail of the protein in the nuclear compartment 
(schematic representation in Figure 12A). 
To check whether also PCDH19 protein could undergo a proteolytic process, like 
other cadherins, we performed experiments on COS-7 cells and HEK293 cells 
transfected with PCDH19-V5 cDNA.  
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Firstly, we treated COS-7 cells with different compounds. We used a proteasome 
inhibitor (MG132) to prevent degradation of small protein fragments and be able to 
visualize all the cleavage products. Further we treated cells with a specific ƴ-
secretase inhibitor (DAPT-1) to understand if this enzyme was involved in PCDH19 
proteolytic process. MG132 treatment allowed the detection of a small fragment, 
whose molecular weight less than 60 KDa corresponds to the C-terminal domain 
(CTF) of PCDH19 protein. Indeed, without MG132 treatment we could not detect the 
band corresponding to the CTF anymore, suggesting that is rapidly degradated by 
proteasome. By contrast, when we treated cells with DAPT-1 and MG132, we were 
not more able to detect the cleaved fragment, suggesting that γ-secretase enzyme is 
involved in PCDH19 proteolytic process (Figure 12B).  
These findings suggest that, at least in heterologous cells, PCDH19 can be cleaved by 
ƴ-secretase enzyme under basal conditions releasing the C-terminal tail that is 
rapidly degraded.   
 
4.4 Nuclear localization of PCDH19 C-terminal domain in 
heterologous cells 
After we established that PCDH19 can be cleaved by γ-secretase enzyme releasing the 
C-terminal domain, we investigated the localization of this fragment since it contains 
a putative NLS. Firstly we performed fractionation experiments on COS-7 cells 
overexpressing PCDH19 and treated with MG132. The results show an enrichment of 
CTF in nuclear compartment (P2 fraction, Figure 12C).    
Further, ICC experiments on HEK293 cells transfected with either PCDH19-V5 cDNA 
or CTF-HA cDNA revealed that MG132 treatment lead PCDH19 distribution both in 
the cytoplasm and in the nucleus (Figure 13A).  Moreover, ICC on HEK293 cells 
transfected with the CTF of PCDH19 showed that the C-terminal tail is able to enter in 
the nuclear compartment and its nuclear detection is clearer after proteasome 
degradation blockage (Figure 13B). 
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All these findings indicate that PCDH19 can be cleaved and that the CTF released is 
able to enter the nucleus of HEK293 and COS-7 cells suggesting a nuclear role of the 
protein. 
  
4.5 Activity dependent nuclear localization of PCDH19 in 
neuronal cells 
Recent works demonstrate that soluble cytoplasmic domains of cadherins, which are 
released after a proteolytic process, are detected into the nucleus after neuronal 
activation where they regulate gene expression (Hambsch, Grinevich et al. 2005, 
Junghans, Haas et al. 2005). 
To investigate the effects of synaptic activity on PCDH19 CTF generation, we treated 
rat primary hippocampal cultures infected with lentivirus of PCDH19-V5 with a set of 
compounds. Firstly, we acutely treated for 1.30 hours mature (DIV19) neurons with 
either bicuculline (BIC), which by blocking GABAA receptors promotes the excitatory 
transmission in neuronal network, or tetradotoxine (TTX), which blocks the voltage-
gated sodium channels and decreases the neuronal network activity, and investigated 
protein localization by ICC experiments.  
Confocal images showed that in control conditions the protein distributes in soma 
compartment and along dendrites, while bicuculline treatment promotes nuclear 
localization of PCDH19 (Figure 14A). These findings are shown clearly in single stacks 
of nuclear compartment. Indeed, after stimulation of neuronal activity there is an 
increased co-localization between PCDH19 and nuclear marker DAPI (Figures 14B). 
Moreover, quantification analysis of fluorescence intensity level of PCDH19 
confirmed that acute bicuculline treatment significant increases the intensity level of 
PCDH19 signal in nucleus, while TTX treatment decreases PCDH19 nuclear 
localization as control condition (mean nucleus: NT 1,230  0,128; BIC 2,013  0,069; 
TTX 1,099  0,252, One-Way ANOVA **p<0,01) (Figure 14C).   
These results indicate that PCDH19 neuronal distribution is highly dependent on 
neuronal activity: in particular, an acute stimulus increases PCDH19 nuclear 
localization suggesting that PCDH19 can transduce external stimuli to nucleus.   
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Next we wondered which receptor influenced PCDH19 cellular distribution. In 
particular we focused on NMDA receptor activity since it is involved in other cadherin 
cleavage and is associated to ƴ-secretase activity (Junghans, Haas et al. 2005). 
To this purpose, we acutely treated for 30 minutes mature neurons overexpressing 
PCDH19-V5 with NMDA to specifically activate the NMDA receptors. Further, we used 
AP5 to specifically block NMDA receptors. ICC experiments revealed that thirteen 
minutes NMDA treatments are sufficient to change PCDH19 distribution, promoting 
its nuclear localization, while AP5 treatment decrease PCDH19 nuclear localization 
(Figure 15A). Also in this case, single stack images of the nucleus clearly show the co-
localization between PCDH19 protein and DAPI signal after NMDA receptors 
activation (Figure 15B). Quantification analysis of PCDH19 fluorescence intensity 
levels confirmed a statistically significant increase of protein nuclear localization 
after NMDA acute treatment compared to control and AP5 treated neurons (mean 
nucleus: CTRL 1,576  0,124; NMDA 2,701  0,377; NMDA+AP5 1,399  0,146, One-Way 
ANOVA *p<0,05) (Figure 7C).  
These findings indicate that PCDH19 changes its neuronal distribution depending on 
NMDA receptor activity and lead us to a new question: is the cleavage of PCDH19 
dependent on NMDA receptors activation? 
 
4.6 PCDH19 cleavage is NMDA activity dependent and mediated 
by ƴ-secretase enzyme 
To get insights into the molecular mechanism that mediates PCDH19 nuclear 
localization in response to NMDA receptors activation, we acutely treated mature 
hippocampal neurons with NMDA and performed different biochemical assays.  
Western blotting analysis on treated neurons revealed that the endogenous full-
length protein (PCDH19-FL) levels significantly decrease after NMDA receptors 
activation while AP5 treatment restores the control levels. Concomitantly with 
PCDH19-FL decrease, PCDH19-CTF significant increases (Figure 16A, One-Way ANOVA 
*p<0,05).   
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These findings were confirmed by western blotting experiments performed on 
hippocampal neurons overexpressing PCDH19-V5. Indeed, also in this case we 
observed a strong decrease of PCDH19-FL after NMDA treatment and an increase of 
CTF (Figure 16B, One-Way ANOVA ***p<0,0001, *p<0,05). 
Moreover, we acutely stimulated AMPA receptors for 30 minutes in mature 
hippocampal neurons and investigated endogenous protein levels. PCDH19-FL levels 
after AMPA treatment are comparable to control conditions, proving the specific 
action of NMDA receptors on PCDH19 cleavage (Figure 17A). 
Then, to go deeper into the mechanism of activity dependent PCDH19 processing we 
performed byotinilation assay on mature hippocampal neurons acutely treated with 
NMDA or NMDA plus AP5. The results show that neuronal activation significantly 
decreased PCDH19 surface levels suggesting that the protein is cleaved in an activity-
dependent manner and released the C-terminal domain with a concomitant decrease 
in its membrane portion. Further, blocking NMDA receptors with AP5, we observed a 
restore of both PCDH19 membrane and CTF levels to the control condition  (CTRL 
3,666  0,744; NMDA 1,375  0,162; NMDA+AP5 2,711  0,359, One-Way ANOVA 
*p<0,05) (Figure 17B). 
Now we know that cadherins cleavage is mediated by ƴ-secretase enzyme that is 
activated by NMDA receptors (Junghans, Haas et al. 2005) and we showed that in 
heterologous cells PCDH19 is cleaved by this enzyme. 
Therefore, we were wondering if this mechanism occurs also in hippocampal 
neuronal cells. To investigate this point, we treated mature hippocampal neurons 
with different compounds: in particular we used MG132 to prevent degradation of 
endogenous CTF; NMDA to stimulate the cleavage; and DAPT-1 to inhibit the ƴ-
secretase enzyme. Western blot analysis revealed that, also in neuronal cells, ƴ-
secretase is responsible for PCDH19 cleavage. Indeed, in the presence of DAPT, 
MG132 and NMDA both endogenous PCDH19-FL and CTF remain similar to control 
conditions (Figure 18A, One-Way ANOVA *p<0,05, **p<0,01).  
Moreover, we confirmed these findings repeating the same treatments on 
hippocampal neuronal cells overexpressing PCDH19. In particular we stimulated cells 
with NMDA and blocked the ƴ-secretase enzyme using DAPT-1. We observed a rescue 
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of both PCDH19-FL and CTF levels after the treatment with DAPT-1 (Figure 18B, One-
Way ANOVA *p<0,05). 
Altogether these results indicate that NMDA receptors activation stimulates the 
cleavage of PCDH19 protein mediated by ƴ-secretase.  
 
4.7 PCDH19 CTF translocates from cytoplasm to the nucleus in 
an activity-dependent manner 
Our results showed that NMDA receptors activation increases nuclear localization of 
PCDH19 (Figure 15) and that, after neuronal activation, the protein is cleaved by ƴ-
secretase enzyme releasing the soluble CTF (Figure 16).   
Therefore, we were asking if is the CTF released by the activity-dependent proteolytic 
process that translocate into the nucleus. To this aim, we performed ICC experiments 
on hippocampal neurons overexpressing either the PCDH19-V5 protein or the CTF-V5 
alone. Single stacks of nuclear compartment showed that the protein distributes in 
part in the nucleus, while almost all the CTF overexpressed localizes in the nuclear 
compartment (Figures 19A and 19B).  
These results indicate that PCDH19, specifically its CTF, enters the nuclear 
compartment suggesting a gene-expression regulatory role of the protein also in 
hippocampal neuronal cells. 
 To confirm that is the C-terminal tail of PCDH19 that localizes in the nuclear 
compartment, we performed fractionation experiments on mature hippocampal 
neuronal cells acutely treated with NMDA or with NMDA plus AP5 and observed 
PCDH19-FL and CTF distribution among different fractions. In basal condition 
PCDH19-FL is present in the total homogenate and membrane/cytoplasmic fractions 
(H.T., S1), while the CTF can be detected also in nuclear aggregates (P2) fraction. 
These findings indicate that PCDH19 cleavage occurs also in basal conditions.  
However, after NMDA receptors activation there is an important enrichment of CTF in 
P2 fraction, as showed by quantification analysis, indicating that the cleaved fragment 
44 
 
obtained after neuronal activation (CTF) is targeted in to nuclear compartment 
(Figure 20).  
Finally, to be sure that the CTF observed in the nucleus is transported from cytoplasm 
to nucleus and that is not the product of new protein synthesis, we treated neurons 
with NMDA to stimulate the cleavage together with an inhibitor of protein 
transcription (DRB). Subsequently, on these neuronal cells we performed the same 
fractionation experiments as before and observed that, even after DRB treatment, the 
CTF is still enriched in P2 fraction (Figure 21). 
These findings indicate that the CTF released after PCDH19 cleavage shuttles from 
cytoplasm to nucleus of neuronal cells suggesting that it can link external stimuli at 
synaptic levels and nuclear compartment. 
 
4.8 Downregulation of PCDH19 in hippocampal neuronal cells 
increases NOVA1 protein and nLSD1 transcript levels 
The results discussed above highlight a novel feature of PCDH19. CTF nuclear 
translocation after NMDA receptors activity gives rise to various questions, in 
particular what genes PCDH19 regulates and what are their roles in the pathogenesis 
of PCDH19-FLE.  
In order to mimic the pathology, we down-regulated PCDH19 expression using 
shRNAs.  
Firstly we designed three different shRNAs that specifically target the rat (sh1873, 
sh1240 and sh2120) and human (only sh2120) PCDH19 transcripts. To test the 
efficacy of these shRNAs, we analyzed PCDH19 endogenous protein level in 
hippocampal neurons lentivirally-infected with the three different shRNAs. All of 
these shRNAs efficiently reduced PCDH19 expression (Figure 22A). 
Then we used the shRNA1873, since it efficiently reduced PCDH19 protein levels, and 
its scrambled sequence as control for PCDH19 silencing experiments, and the human 
PCDH19-V5 cDNA together with shRNA1873 to rescue PCDH19 endogenous levels. 
We observed that scrambled sequence is not able to silence PCDH19 protein and that 
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the lentiviral expression of PCDH19-V5 cDNA together with its specific shRNA1873 
allows maintaining the control level of PCDH19 protein (Figure 22B).    
Interestingly, we observed that in hippocampal neurons infected with PCDH19 
shRNA there was a significant increase of NOVA1 protein levels. These results were 
obtained with ICC and western blotting experiments (Figure 22C-D, t-test *p<0,05, 
One-Way ANOVA *p<0,05). NOVA1 regulates alternative splicing of various genes and 
it is involved in the maintenance of inhibitory/excitatory neuronal network balance.   
Since NOVA1 promotes LSD1 neuronal isoform (neuroLSD1) (Rusconi, Paganini et al. 
2015), we investigated if also the mRNA levels of this isoform were changed after the 
downregulation of PCDH19. The results showed a significant increase of neuroLSD1 
transcript compared to control conditions (scramble and rescue, Figure 22E, One-Way 
ANOVA **p<0,01). 
These findings represent a new territory of investigation to get into the 
pathophysiologic basis of the disease. In particular they suggest a new mechanism by 
which PCDH19 loss of function in PCDH19-FL epilepsy could affect a neuro-restricted 
epigenetic corepressor (LSD1), which modulates circuitry excitability.  
 
4.9 CTF proteolytic processed is able to associate with LSD1 and 
neuroLSD1   
Since the CTF of PCDH19 protein is cleaved following NMDAR activity and that 
NOVA1 and neuroLSD1 are important for neuronal homeostasis, we were wondering 
if there is a connection between PCDH19 cleavage and NOVA1/neuroLSD1 pathways. 
To this aim, we first checked the interactions. Firstly, we performed pull-down 
experiments and coimmunprecipitations (Co-IP) in HEK293 cells using PCDH19 
protein or its CTF as show in Figure 23A.  
In pull-down experiments we used CTF fused to GST as a bait that was incubated with 
lysates of HEK293 cells transfected with LSD1-HA or NOVA1-HA constructs. We 
found that LSD1 is able to interact with the C-terminal domain of PCDH19, while 
NOVA1 is not (Figure 23B).  
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Then, we transfected HEK293 cells with PCDH19-V5 together with either LSD1-HA, 
neuroLSD1-HA or NOVA1-HA. In all these experiments we immunoprecipitated 
PCDH19 and the results show that both LSD1 and neuroLSD1 can associate with 
PCDH19. By contrast NOVA1 cannot (Figure 23C). 
To reduce the region of interaction of PCDH19 with neuroLSD1 and LSD1, we 
performed Co-IP experiments in HEK293 cells co-transfected with LSD1-HA or 
neuroLSD1-HA and different PCDH19 constructs. In particular we used the CTF-V5 
and the PCDH19 with Δ844-1161aa (Figure 24A). We found that the sequence of 
PCDH19 protein that is involved in the interaction with LSD1 and neurLSD1 is in the 
CTF, in particular between aa844 and 1161 (Figure24B-C).  
Finally, to establish whether the two common motifs of cadherin family proteins 
(CM1 and CM2) were involved in this interaction, we tested PCDH9 that belongs to 
the protocadherin family and contains CM1, CM2 and CM3 domains (Figure 25A). We 
co-transfected HEK293 cells with PCDH9-myc and either LSD1-HA or neuroLSD1-HA 
and immunoprecipitated for PCDH9-myc. The results showed that LSD1 and 
neuroLSD1 are not able to interact with PCDH9 protein, indicating that CM1 and CM2 
are not sufficient to mediate the interaction and other regions between aa844 and 
1161 are involved (Figure 25B). 
Altogether these findings suggest the existence of a complex between the CTF of 
PCDH19 protein and two important epigenetic corepressor factors, LSD1 and its 
neuro-restricted isoform neuroLSD1. 
 
4.10 NeuroLSD1splicing is regulated by NMDA activity  
Previous studies revealed that, in response to epileptogenic stimuli, downregulation 
of NOVA1 reduces the expression of neuroLSD1 to homeostasis (Eom, Zhang et al. 
2013, Rusconi, Paganini et al. 2015). We demonstrated that PCDH19 is cleaved after 
strong activation of NMDA receptors and releases its CTF that goes into the nucleus.  
After proving that CTF can interact with LSD1 and neuroLSD1, we were asking if the 
same activity that stimulated PCDH19 cleavage could regulate LSD1/neuroLSD1 
balance. If this is the case, we can hypothesize that PCDH19 cleavage together with 
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LSD1/neuroLSD1 corepressing actions might linked to each other in the same 
regulatory pathway of neuronal excitability. 
To this purpose, we firstly treated mature hippocampal neurons with NMDA and 
NMDA plus AP5 and analyzed LSD1 protein levels by western blotting. The 
quantification showed that there is a statistically significant increase of LSD1 protein 
levels after NMDA receptors activation and an important decrease after AP5 
treatments (Figure 26A, One-Way ANOVA *p<0,05). 
Thus, we demonstrated that LSD1 can be regulated by the same activity pattern that 
stimulates PCDH19 cleavage.  
To go deeper into the investigation of this mechanism, in particular to be able to 
discriminate between the two isoforms of LSD1, we performed also mRNA analysis on 
hippocampal neuronal cells treated as before. The results show that there is an 
important decrease in the percentage of neuroLSD1 isoform after NMDA receptors 
stimulation (Figure 26B, One-Way ANOVA **p<0,01, ***p<0,0001) 
Altogether these results suggest that after a strong activation of NMDA receptors the 
levels of LSD1 and neuroLSD1 change in order to restore neuronal cells into a 
homeostasis. Further, CTF released after PCDH19 cleavage could solve a crucial role 
in this regulatory mechanism, through the interaction with LSD1 and neuroLSD1 
elements.       
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5. FIGURES AND LEGENDS 
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Figure 10: PCDH19 is highly expressed in cortex and hippocampus and localizes 
at synapse. (A) Western blot of adult rat brain homogenates using anti-PCDH19 and 
anti-α tubulin. Quantification analysis of PCDH19 levels (right panel) showing that 
PCDH19 is expressed at high level in cortex and hippocampus. (HIPPO: hippocampus; 
CEREB: cerebellum). (B) Adult mouse brain fractionation showing the presence of 
PCDH19 in crude synaptosomes (P1: nuclear fraction; S1 and S2: cytosol and light 
membranes; P2: crude synaptosomal pellet). (C) Biotinylation experiment on mature 
hippocampal neurons showing both surface and intracellular expression of PCDH19. 
(D) ICC performed on COS-7 cells (left) and mature hippocampal neurons (right) 
overexpressing PCDH19-V5 showed that PCDH19 is recruited at cell-cell contacts 
(zoom boxes).    
 
 
 
50 
 
 
51 
 
Figure 11: PCDH19 distributes both in immature and mature neurons, both in 
inhibitory and excitatory cells. (A) Confocal images of hippocampal neuronal cells 
fixed at DIV4 and DIV18 and immunostained for DAPI and PCDH19 to visualize nuclei 
and endogenous protein respectively. PCDH19 is abundantly expressed in immature 
neurons, while it distributes heterogeneously in mature neuronal cells. (B) Confocal 
images of hippocampal neuronal cells fixed at DIV12 and DIV19 and immunostained 
for PCDH19 and MAP2 to visualize endogenous protein and cellular morphology 
respectively. PCDH19 distribution along dendritic shaft (neurons DIV12); PCDH19 
punctuated pattern (neurons DIV19). (C) Confocal images of mature hippocampal 
neurons stained for PCDH19, PSD95 and α1 subunit of GABAA receptor. Zoom boxes 
showing partial co-localization between PCDH19 and both PSD95 and α1 subunit of 
GABAA receptor. 
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Figure 12: proteolytic cleavage of PCdh19 in heterologous cells. (A) Schematic 
representation of PCDH19 protein and its putative cleavage site for ƴ-secretase. On 
the right are shown ƴ-secretase substrates: red amino acids represent the 
accommodation site for the enzyme; underlined valines represent the site of action of 
the enzyme. In the transmembrane domain of PCDH19 there are two valine residues 
(aa 683, 698) that could be the sites of action for ƴ-secretase. Indication of a putative 
nuclear localization sequence (NLS) in the C-terminal domain of PCDH19, between aa 
771-782. (B) Schematic representation of CTF released after PCDH19 cleavage (left). 
Western blot of COS-7 cells overexpressing PCDH19 and treated with MG132 and 
DAPT to prevent proteasome degradation and inhibit ƴ-secretase action respectively 
(10 μM, 1.30 h, 37°C). Detection of CTF after MG132 treatment. DAPT inhibits of 
PCDH19 cleavage even in the presence of MG132. (C) Fractionation experiment on 
COS-7 cells transfected with PCDH19 and treated with MG132. CTF (indicated by red 
arrow) is enriched in the nuclear compartment (H.T.: total homogenate; S2: 
cytoplasmic compartment; P2: nuclear compartment). 
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Figure 13: PCDH19 and CTF are enriched in the nucleus of heterologous cells. (A) 
Confocal images of HEK293 cells transfected with PCDH19-V5 and immunostained for 
V5 and DAPI to visualized overexpressed protein and nuclei respectively. After 
MG132 treatment the protein localizes also in the nuclear compartment: better 
shown by single stack images of the nucleus (boxes at the right). (B) Confocal images 
of HEK293 cells transfected with CT-HA (C-terminal domain of PCDH19) and 
immunostained for HA and DAPI to visualized overexpressed protein and nuclei 
respectively. The fragment is enriched in the nucleus and even more after MG132 
treatment: better shown by single stack images of the nucleus (boxes at the right)  
(MG treatment: 10 μM, 1.30 h, 37°C). 
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Figure 14: Activity dependent nuclear localization of PCDH19 in hippocampal 
neurons. (A) Confocal images of hippocampal mature neurons overexpressing 
PCDH19, immunostained for V5, DAPI and MAP2 and acutely treated with bicuculline 
(BIC, 40μM, 1.30 h, 37°C) or tetradotoxine (TTX, 2μM, 1.30 h, 37°C). PCDH19 enriched 
in nucleus after BIC treatment. (B) Single stack of above neuronal nuclei showing 
better PCDH19 nuclear distribution after BIC treatment. On the other hand, TTX 
blocks PCDH19 enrichment in nuclear compartment. (C) Quantification analysis of 
PCDH19 fluorescence intensity level in nuclear compartment confirming the above 
observations (**p<0,01, One-Way ANOVA analysis). 
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Figure 15: NMDA dependent nuclear localization of PCDH19 in hippocampal 
neurons. (A) Confocal images of hippocampal mature neurons overexpressing 
PCDH19, immunostained for V5, DAPI and MAP2 and acutely treated with NMDA 
(50μM, 30min, 37°C) or NMDA+AP5 (NMDA 50μM, AP5 100μM, 1.30 h, 37°C). 
PCDH19 enriched in nucleus after NMDA treatment. (B) Single stack of above 
neuronal nuclei showing better PCDH19 nuclear distribution after NMDA treatment. 
On the other hand, AP5, by blocking NMDA receptors, prevents PCDH19 enrichment 
in nuclear compartment. (C) Quantification analysis of PCDH19 fluorescence intensity 
level in nuclear compartment confirming the above observations (*p<0,05, One-Way 
ANOVA analysis). 
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Figure 16: PCDH19 cleavage in hippocampal neurons is NMDA dependent. 
Western blot of hippocampal mature cells using antibodies against PCDH19, V5 and 
GAPDH to detect endogenous protein (A) or overexpressed PCDH19-V5 (B). PCDH19 
full length protein is indicated by red arrow, while CTF is indicated by red asterisk. 
Quantification analysis (histograms below) revealed a significant decrease of 
PCDH19-FL and increase of CTF after NMDA treatment. PCDH19-FL and CTF levels 
are as control after AP5 treatments, indicating that NMDA stimulates PCDH19 
cleavage and CTF release. (NMDA 50μM, 30min, 37°C; AP5 100μM, 30 min, 
37°C;***p<0,0001, *p<0,05, One-Way ANOVA analysis). 
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Figure 17: NMDA decreases PCDH19 neuronal surface levels. (A) Western blot of 
mature hippocampal neuronal cells, acutely treated with AMPA, using PCDH19 and 
GAPDH antibodies. Quantification analysis of PCDH19 full length protein (histogram 
on the right) showing that AMPA treatment doesn’t reduce PCDH19-FL protein 
(AMPA 50μM, 30 min, 37°C). (B) Byotinilation assay on mature hippocampal neurons 
using anti-PCDH19 antibody, to visualize endogenous protein, anti-GAPDH and anti-
transferrin to normalize input and biotinylated protein. Quantification analysis 
(histograms below) show a significant reduction of not only PCDH19 total protein but 
also PCDH19 surface levels after NMDA treatment. AP5 treatment prevents the 
decrease of both PCDH19 total protein and surface levels. (NMDA 50μM, AP5 100μM, 
1.30 h, 37°C, *p<0,05, One-Way ANOVA analysis). 
64 
 
 
65 
 
Figure 18: PCDH19 is cleaved by ƴ-secretase enzyme. Western blot of hippocampal 
mature cells using antibodies against PCDH19, V5 and GAPDH to detect endogenous 
protein (A) or overexpressed PCDH19-V5 (B). Cells were treated with different 
compound: NMDA, MG132 for endogenous protein to prevent proteasome 
degradation, and DAPT to inhibit ƴ-secretase. CTF is indicated by red arrow (A), 
while PCDH19-FL is indicated by red arrow and CTF by red asterisk (B). 
Quantification analysis (histograms below) revealed a significant decrease of 
PCDH19-FL and increase of CTF after NMDA treatment. PCDH19-FL and CTF levels 
are almost as control after DAPT treatments, indicating that ƴ-secretase mediates 
PCDH19 cleavage and CTF release. (NMDA 50μM, 30min, 37°C; MG132, DAPT 10μM, 
1.30 h, 37°C;**p<0,01, *p<0,05, One-Way ANOVA analysis). 
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Figure 19: CTF localizes in nuclei of hippocampal neuronal cells. (A) Confocal 
images of hippocampal mature neurons transfected with PCDH19-V5 entire protein 
(A) or C terminal domain (B) and stained for V5 and DAPI. PCDH19 distributes both  
in cytoplasm and in nucleus (A), while CT is mainly enriched in the nucleus (B). 
Nuclear localizations are better shown in single stack images (boxes below confocal 
images). These indicates that is the C-terminal domain of PCDH19 that localizes in the 
nuclear compartment.  
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Figure 20: CTF translocates from cytoplasm to the nucleus after NMDA treatment. 
(A) Fractionation experiments of hippocampal neurons showing PCDH19 endogenous 
protein. Quantification analysis (histogram below) indicates that NMDARs activation 
leads to increase in CT fragment production (CT levels in P2 fraction compared 
PCDH19-FL in S1 fraction) that localises in P2 compartment, while AP5 treatment 
prevents PCDH19 cleavage. GAPDH and LSD1 are used as cytoplasmic and nuclear 
markers respectively. PCDH19 full-length is indicated by black arrows, while CTF is 
indicated by red arrows. (NMDA 50μM, AP5 100μM, 30 min, 37°C; H.T.: total 
homogenate; S1: membrane/cytoplasmic fraction; S2: nuclear soluble fraction; P2: 
nuclear insoluble fraction). 
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Figure 21: CTF produced after PCDH19 cleavage is transport from cytoplasm to 
nucleus. (A) Fractionation experiments of hippocampal neurons showing PCDH19 
endogenous protein distributions among different fractions. Neurons were treated 
with NMDA to stimulate PCDH19 cleavage and with DRB to block protein 
transcription. Blots show that, even after DRB treatment, CTF localizes in the nuclear 
fraction (P2), indicating that this fragment is not a result of new protein synthesis, 
but, after PCDH19 cleavage, it translocates into nucleus. (DRB 10μM, 1h, 37°C, NMDA 
50μM, 30 min, 37°C;  H.T.: total homogenate; S1: membrane/cytoplasmic fraction; S2: 
nuclear soluble fraction; P2: nuclear insoluble fraction). 
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Figure 22: Downregulation of PCDH19 in hippocampal neuronal cells increases 
NOVA1 and neuroLSD1 levels. Validation of PCDH19 shRNAs. Lentiviral-mediated 
infection of neurons with pLVTHM-GFP, pLVTHM-GFP-shRNA1873, -sh2120, -sh1240 
(A) and with pLVTHM-GFP-scrambled shRNA1873, pLVTHM-GFP-shRNA1873, 
FuwPCDH19-V5 (B). Immunoblots refer to DIV10 cortical neurons infected at DIV3. 
ShRNAs downregulate PCDH19. FuwPCDH19-V5 infection rescues PCDH19 level. (C) 
Immunostaining of hippocampal mature neurons infected with shPCDH19 or 
scrambled, both expressing GFP, and marked for NOVA1 protein. The fluorescence 
intensity levels of NOVA1 is higher in neurons infected with shPCDH19 compared 
with the control expressing scrambled as shown in histogram (*p<0,05, t-test 
analysis). (D) These data are confirmed by western blot analyses performed on 
hippocampal mature neurons: there is a significant increase in NOVA1 protein levels 
in neurons infected with shPCDH19 compared to the two control conditions (*p<0,05, 
One-Way ANOVA analysis). (E) mRNA analyses of neuroLSD1 performed in 
hippocampal mature neurons reveal a significant increase in the ratio of 
neuroLSD1/LSD1 in neurons infected with shPCDH19 compared both to control 
condition (scrambled) and to neurons overexpressing PCDH19 (**p<0,01, One-Way 
ANOVA analysis).  
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Figure 23: CTF is able to interact with LSD1 and neuroLSD1 protein. (A) Schematic 
representation of PCDH19 used for Co-IP experiments and of C-terminal construct of 
PCDH19 used for Pull-down assay. (B) Pull-down assay performed in HEK293 cells 
transfected with LSD1-HA or NOVA1-HA. The results show that LSD1 is able to 
interact with the C-terminal fragment of PCDH19, while NOVA1 doesn’t interact. (C) 
Co-immunoprecipitation experiments in HEK293 cells transfected with PCDH19-V5 
and LSD1-HA, neuroLSD1-HA or NOVA1-HA. The results show that LSD1 and nLSD1 
can associate with PCDH19. NOVA1 not associate with PCDH19. 
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Figure 24: Reduction of CTF interacting portion with neuroLSD1 and LSD1. (A) 
Schematic representation of CTF and PCDH19Δ844-1161 (PCDH19-E3) used for Co-
IP experiments and of the resulting interacting part of PCDH19. Co-
immunoprecipitation experiments in HEK293 cells transfected with LSD1-HA, 
neuroLSD1-HA or NOVA1-HA and CT-V5 (B) or PCDH19-E3 (C). The results show that 
LSD1 and neuroLSD1 can associate with CT but not with PCDH19-E3 reducing the 
interacting part of CT. 
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Figure 25: Reduction of CTF interacting portion with neuroLSD1 and LSD1. (A) 
Schematic representation of PCDH9 used for Co-IP experiments and of the resulting 
interacting part of PCDH19. Co-immunoprecipitation experiments in HEK293 cells 
transfected with PCDH9 and LSD1-HA or neuroLSD1-HA. Red asterisks indicate 
PCDH9 specific band. The results show that LSD1 and neuroLSD1 cannot associate 
with PCDH9, those excluding the common motifs (CM1 and CM2) in the interaction. 
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Figure 26: neuroLSD1 splicing is regulated by NMDA. (A) Western blot of mature 
hippocampal neurons treated with the compound that stimulates PCDH19 cleavage 
and using anti-LSD1 antibody. Histogram show that after NMDA treatment there is a 
significant increase in LSD1 protein levels, while AP5 prevents this increase 
(**p<0,01, *p<0,05, One-Way ANOVA analysis). (B) mRNA analyses of neuroLSD1 
performed in hippocampal mature neurons reveal a significant decrease in the ratio 
of neuroLSD1/LSD1 in neurons treated with NMDA compared both to control 
condition and to neurons treated with AP5 (***p<0,0001, One-Way ANOVA analysis). 
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6. DISCUSSION 
PCDH19 gene was identified in 2008 as the causative gene of PCDH19-FLE and is now 
considered the second gene, after the Dravet syndrome gene SCN1A, most clinically 
relevant in epilepsy (Dibbens, Tarpey et al. (2008)). 
To date, little is known about PCDH19 biological functions and about the mechanisms 
that give rise to the pathology, which precludes effective therapy.  
Our work is aimed to investigate PCDH19 physiological functions in order to 
understand the molecular pathways that are impaired in patients and highlight new 
therapeutic targets. 
In particular, in this work we demonstrated that PCDH19 is highly expressed in 
cortex and hippocampus and localizes at synapses. Further, we found that it is 
detectable in immature and mature hippocampal neurons, both in inhibitory and 
excitatory cells, suggesting different roles for the protein during neuronal 
development and neuronal network formation as well as in synaptic function.  
Importantly, we revealed through this work a new PCDH19 feature. Indeed, we 
demonstrated that, after neuronal activation mediated by NMDA receptors, PCDH19 
is cleaved by ƴ-secretase and releases its C-terminal domain that is targeted to the 
nucleus probably to regulate gene expression.  
Further, we identified two putative interactors of PCDH19-CTF, LSD1 and neuroLSD1. 
These two splicing isoforms of LSD1, upon their association with different complexes, 
solve crucial roles in the transcription regulation of several target genes mainly 
involved in the maintenance of homeostatic balance between neuronal inhibition and 
excitation Rusconi, Paganini et al. (2015). 
 
6.1 PCDH19 protein expression and its involvement in PCDH19-
FLE pathology     
Since little is known about PCDH19, we firstly investigated its expression in brain and 
found that it is enriched in hippocampus and cortex and in crude synaptosomes of 
hippocampal neurons. PCDH19-FLE pathology is characterized by several clinical 
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features, including epilepsy, cognitive impairments, behavioral disturbances and 
autism that exhibits different phenotypic degrees in patients (Scheffer, Turner et al. 
2008). Our findings regarding PCDH19 expression are in line with these clinical 
aspects, further suggesting an involvement of the protein in cognitive processes. To 
go deeper into neuronal functions of PCDH19, we found that it is expressed both in 
immature and mature neurons and in inhibitory and excitatory neuronal cells. These 
results suggest that the protein could be involved in several roles according to the 
type of neurons in which it is expressed and the developmental period. One important 
feature of FLE is the onset of epileptic seizures during infancy and childhood, 
suggesting a defect in inhibitory/excitatory circuitry caused by PCDH19 gene 
mutations (Scheffer, Turner et al. 2008). PCDH19 is probably involved in the 
maintenance of neuronal excitatory and inhibitory balance. Further, PCDH19 
presence in immature neurons evoked an important role of this protein during 
neuronal development for circuit formation, in particular it could be fundamental for 
correct synaptogenesis, such as other cadherins like N-Cadherin (Frank and Kemler 
2002).  
One model that tries to explain the unusual manifestation pattern of PCDH19-FLE 
pathology is the “cellular interference”, that considers the cell-cell scrambled 
communication due to tissue mosaicism as the principal cause of the pathology 
(Depienne, Bouteiller et al. 2009). In line with this model we demonstrated that 
PCDH19 protein is expressed on the plasma membrane, in particular at cell-cell 
contacts, suggesting an important role of PCDH19 in intercellular adhesion. 
        
6.2 PCDH19 is cleaved in an activity-dependent manner by ƴ-
secretase enzyme 
PCDH19 belongs to the δ2-protocadherins subfamily. Little is known about the 
neuronal roles of these proteins. However, protocadherins appear to be important for 
circuit and synapse formation through their adhesive properties. Recent studies 
reveal a new intracellular role of some cadherins and protocadherins and focus their 
attention on intracellular signaling (Depienne, Gourfinkel-An et al. 2012). There are 
evidences that protocadherins, besides their cell-cell adhesion functions, play 
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important role at intracellular and nuclear levels. In particular, they exert this action 
through a proteolytic process, a mechanism that has been observed for some 
cadherins such as N-cadherin, E-cadherin and ƴ-protocadherins which are cleaved 
both exctracellularly and intracellularly by different enzymes (Junghans, Haas et al. 
2005). 
In this work we demonstrated that also PCDH19 protein is cleaved intracellularly by 
ƴ-secretase both in heterologous systems and in hippocampal neuronal cells. PCDH19 
cleavage leads to the release of its C-terminal domain, which is difficult to detect since 
it is rapidly degradated by proteasome. Interestingly, we showed that PCDH19 
proteolytic process depends on NMDA receptors activation. In line with this evidence, 
recent studies showed that ƴ-secretase complex is also located at synaptic sites and 
its action could be stimulated by NMDA receptors activity (Thompson, Otis et al. 
2004). 
These findings lead to a new territory of investigation for PCDH19 functions. Further, 
the observation that the cleavage depends on neuronal activity suggests that PCDH19 
has a role in transducing external stimuli to intracellular responses. This was 
demonstrated for other cadherins, such as N-cadherin and ƴ-protocadherins, that, 
after NMDA stimuli, undergo proteolytic cleavage and release their cytoplasmic 
domains which could solve intracellular signaling roles (Junghans, Haas et al. 2005). 
We also demonstrated that NMDA activity stimulating PCDH19 cleavage leads to a 
decrease in the full-length form of the protein present at membrane surface, 
suggesting that consequence of the neuronal activity is the reduction of PCDH19-
mediated adhesion. However, it is important to investigate more the extracellular 
domain of the protein to define its roles, analyzing the consequences of the cleavage. 
The proteolytic cleavage is usually characterized by two steps: the first one is 
mediated by metalloproteases and occurs at extracellular level; the second one is 
mediate by γ-secretase and occurs at intracellular level. Those it would be interesting 
to know which metalloproteases act on the extracellular domain of PCDH19 and if the 
domain is released in the extracellular space to interact with other proteins or simply 
degradated.  
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6.3 C-terminal domain of PCDH19 goes from cytoplasm to 
nucleus in response to neuronal activity 
 After we established that PCDH19 is cleaved by ƴ-secretase after NMDA receptors 
activity and, as a consequence, its C-terminal domain is released, we focused our 
attention on the roles of this fragment. In particular, since it contains a NLS, we 
investigated its nuclear localization. Firstly, we demonstrated that NMDARs activity 
regulates PCDH19 distribution in neuronal cells. Indeed, the protein, detected by an 
antibody specifically directed to PCDH19 C-terminal domain, localizes more in the 
nuclear compartment when neurons are stimulated by NMDA. Then, we showed that 
is the C-terminal domain of PCDH19 that enters the nucleus after neuronal activity 
and cleavage mediated by ƴ-secretase.  
For neuronal cells it is crucial to converge and integrate in the nucleus synaptic signal 
to determine a genomic response able to solve proper neuronal functions such as 
development, plasticity and survival. Recently, it has been shown that synaptic 
proteins entering the nuclear compartment after neuronal activity play important 
role in synapse-to-nucleus communications (West, Griffith et al. 2002, Deisseroth, 
Mermelstein et al. 2003, Thompson, Otis et al. 2004, Greer and Greenberg 2008). 
Our results revealed a completely new role of PCDH19 protein. In particular we 
demonstrated that PCDH19, through its C-terminal domain, is able to connect an 
external stimulus from synaptic compartments, where it is located, to the nucleus of 
the cells probably in order to regulate gene expression in response to neuronal 
activity. Further, we demonstrated that CTF, which accumulates in the nucleus after 
NMDA receptors activation, is not the product of new protein synthesis, but is likely 
the result of a transport from synapse to the nucleus of neuronal cells. Thus, we could 
speculate that PCDH19-CTF is a new protein messenger with a role in synapse-to-
nucleus communication linking neuronal activity with transcriptional regulation. It is 
fundamental to investigate what genes it regulates in order to clarify PCDH19 
functions, in particular which pathways could be impaired in PCHD19-FLE pathology.   
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6.4 PCDH19-CTF is part of LSD1/neuroLSD1 complex and 
regulates gene expression 
Final experiments of this work aimed to discover nuclear functions of PCDH19. We 
demonstrated that downregulation of PCDH19 protein mediated by shRNA 
expression in neuronal cells, in order to mimic pathological conditions, increases 
NOVA1 protein levels and neuroLSD1 mRNA levels. 
NOVA1, LSD1 and neuroLSD1 are important elements both for the correct neuronal 
development and for the maintenance of excitatory/inhibitory neuronal balance. 
NOVA1 promotes neuroLSD1 splicing isoform, which, together with different 
partners, regulates gene expression. In particular, by histone epigenetic 
modifications, it activates transcriptions of neuronal genes involved in the 
maintenance of excitatory/inhibitory balance. It also acts as a corepressor factor for 
LSD1, which repress gene transcription. High levels of neuroLSD1 result in increased 
neuronal excitability. In order to clarify the role of LSD1/neuroLSD1, it has been used 
a mouse model that completely lacks neuroLSD1 isoform expression. The authors 
demonstrated that these mice were protected from the onset of epileptic seizures 
(Rusconi, Paganini et al. 2015).  
Since we demonstrated that the downregulation of PCDH19 alters NOVA1 and 
neuroLSD1 expression levels, we propose two hypothesis: the first one considers 
PCDH19 as a transcriptional regulator of genes encoding for these two elements, thus, 
when there is less PCDH19 there is an imbalance in NOVA1 and neuroLSD1 
transcripts level; in the second hypothesis, we consider PCDH19 protein as a cofactor 
of neuroLSD1 that could act on regulation of gene transcription, and loss of function 
of PCDH19 could leads to a deficit in appropriate chromatin modifications that create, 
as a loop, an imbalance in neuroLSD1 transcripts level. 
To investigate if these hypotheses could be both or just one true, we analyzed deeply 
PCDH19 protein interactions. In particular, we found that PCDH19 C-terminal domain 
is able to specifically interact with both LSD1 and neuroLSD1 isoform, at least in 
heterologous systems. These results suggest the existence of a complex with PCDH19 
and LSD1/neuroLSD1, but we cannot exclude also the first hypothesis. More 
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experiments have to be done in order to clarify the mechanism of action that connects 
PCDH19-CTF with LSD1/neuroLSD1.  
Further, we observed that the same neuronal activity that regulates PCDH19 cleavage 
(acute treatments with NMDA) is able to regulate neuroLSD1 transcript levels, 
drastically reducing its expression as a regulatory negative feedback: the more 
neuronal activity is present, the less neuroLSD1 isoform is produced in order to 
restore neuronal cells into a homeostatic state regarding its excitability. These 
findings suggest that the CTF produced after strong NMDA stimuli could solve a 
crucial role in this regulatory mechanism, through the interaction with LSD1 and 
neuroLSD1 elements.  
These findings lead to hypothesize that in patients the absence of PCDH19 
determines an increase in neuroLSD1 levels and, as a consequence, in neuronal 
excitability. Further, the same neuronal activity that stimulates PCDH19 cleavage 
decreases neuroLSD1 levels, acting as a regulatory negative feedback that decrease 
neuronal excitability. Thus the presence of PCDH19 and the release of its C-terminal 
domain after cleavage seem to be fundamental in the regulation of neuronal 
homeostasis. Neuronal cells without PCDH19 have impairment in the regulation of 
excitability that can lead to an excitation/inhibition imbalance in the whole neuronal 
network. 
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7. CONCLUSIONS AND FUTURE PERSPECTIVES 
In this work we found a completely new role of PCDH19 protein, demonstrating that 
it is cleaved after NMDA receptors activity and the released C-terminal domain enters 
the nucleus. Thus, PCDH19-CTF becomes an important element in synapse-to-nucleus 
communications and probably regulates gene expression in response to neuronal 
activity. Further, we found a pathway in which CTF could be involved, related to 
LSD1/neuroLSD1 transcription factors. These findings improve the knowledge of 
PCDH19-FLE pathological mechanisms. Now, it is fundamental to investigate the CTF 
target genes, taking advantages of microarray techniques, in order to amplify the 
knowledge on the pathways in which PCDH19 could play a role. Once we obtain these 
results, it would be interesting to investigate if these pathways are impaired in 
pathological conditions. This information would facilitate the identification of new 
therapeutic targets.       
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